All-canine anti-canine PD-1 antibodies and uses thereof
By developing specific antibodies or antigen binding fragments against dog PD-1, the problem of lack of anti-dog PD-1 antibodies in the treatment of canine cancer in the veterinary field has been solved, effective treatment of canine cancer has been achieved, and the treatment effect has been enhanced and reduces the risk of immune response.
Patent Information
- Application Number
- CN202280091132.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-10
- Filing Date
- 2022-12-09
- Publication Date
- 2024-11-08
AI Technical Summary
The lack of anti-dog PD-1 antibodies against canines in the veterinary field has led to the inability to effectively utilize immune checkpoint inhibition therapy to treat canine cancer.
An antibody or antigen-binding fragment thereof, including specific amino acid sequences, was developed to block PD-1 on tumor-specific T cells, to achieve Treatment of canine cancer.
By blocking the interaction of cPD-1 with its ligand, it enhances the therapeutic effect on canine cancer, provides a non-immunogenic dog antibody, reduces the risk of inducing immune responses in dogs, and improves the safety of treatment Sex and effectiveness.
Smart Images

Figure BDA0004981972470000341 
Figure BDA0004981972470000351 
Figure BDA0004981972470000361
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Patent Application No. 63 / 288,284, filed on December 10, 2021, which is hereby incorporated by reference in its entirety. Background Art
[0003] The immune checkpoint inhibitors (ICIs) pembrolizumab and nivolumab have revolutionized the treatment of patients with different cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer. This class of ICI therapies works by blocking receptors that negatively regulate the function of cytotoxic T cells. In effect, the ICIs act to block signaling pathways that otherwise inhibit T cell function. Immune checkpoint receptors normally play a key role in preventing immune responses from becoming toxic, but many cancers exploit these negative signals to weaken T cell immune responses against them, often by expressing ligands for immune checkpoint receptors expressed on cytotoxic T cells.
[0004] Immunocompetent dogs develop spontaneous tumors that display hallmark features such as chromosomal aberrations, molecular subtypes, immune signatures, tumor heterogeneity, metastatic behavior, and response to chemotherapy. However, the potential clinical benefits of checkpoint inhibition in treating canine cancer patients cannot be realized due to the current lack of fully canine, commercially available anti-canine PD-1 (cPD-1) antibodies in veterinary medicine.
[0005] There is a need in the art for the development of non-immunogenic canine antibodies directed against immune checkpoint molecules that can be used to treat veterinary cancers in canine subjects by blocking PD-1 on tumor-specific T cells. Summary of the invention
[0006] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain complementary determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, 27 or 43, a heavy chain complementary determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, 28 or 44, a heavy chain complementary determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, 29 or 45, a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, 30 or 46, a light chain complementary determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, 31 or 47, and a light chain complementary determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 6, 32 or 48.
[0007] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:7, 9, 33 or 49; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:11, 35 or 51.
[0008] In some embodiments, the antibody or its antigen-binding fragment comprises: an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 19, 21, 23, 39 or 55, and an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 25, 41 or 57.
[0009] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
[0010] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 7, 9, 33 or 49; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 11, 35 or 51.
[0011] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0012] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0013] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain complementary determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain complementary determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, a heavy chain complementary determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, a light chain complementary determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, and a light chain complementary determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 6.
[0014] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 7 or 9; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 11.
[0015] In some embodiments, the antibody or its antigen-binding fragment comprises: an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25.
[0016] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11.
[0017] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 7; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 11.
[0018] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 9; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 11.
[0019] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 25.
[0020] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence listed in SEQ ID NO: 19, and an immunoglobulin light chain comprising the amino acid sequence listed in SEQ ID NO: 25.
[0021] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25.
[0022] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 23, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25.
[0023] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain complementary determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 27, a heavy chain complementary determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 28, a heavy chain complementary determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 29, a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 30, a light chain complementary determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 31, and a light chain complementary determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 32.
[0024] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:33; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:35.
[0025] In some embodiments, the antibody or its antigen-binding fragment comprises: an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:39, and an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:41.
[0026] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 33; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 35.
[0027] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 33; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 35.
[0028] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 39, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 41.
[0029] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 39, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 41.
[0030] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain complementary determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO:43, a heavy chain complementary determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO:44, a heavy chain complementary determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO:45, a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO:46, a light chain complementary determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO:47, and a light chain complementary determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO:48.
[0031] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:49; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:51.
[0032] In some embodiments, the antibody or its antigen-binding fragment comprises: an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:55, and an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO:57.
[0033] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 49; and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 51.
[0034] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 49; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 51.
[0035] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 55, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence set forth in SEQ ID NO: 57.
[0036] In one aspect, disclosed herein is an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises: an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 55, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 57.
[0037] In some embodiments, the antibody or its antigen-binding fragment is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these. In some embodiments, the antibody or its antigen-binding fragment is selected from a full-length antibody, Fab, a single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a diabody. In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody is a canine or caninized antibody. In some embodiments, the antibody is a canine antibody. In some embodiments, the antigen-binding fragment is a scFv. In some embodiments, the specific binding of the antibody or its antigen-binding fragment to cPD-1 disrupts the interaction of cPD-1 with the ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0038] In one aspect, disclosed herein is a canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1).
[0039] In one aspect, disclosed herein is a canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), comprising an antibody or antigen-binding fragment thereof as described herein. In some embodiments, the specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0040] In one aspect, disclosed herein is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising: a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2 and HCDR3, wherein HCDR1 comprises an amino acid sequence selected from SEQ ID NOs: 1, 27 and 43, HCDR2 comprises an amino acid sequence selected from SEQ ID NOs: 2, 28 and 44, and HCDR3 comprises an amino acid sequence selected from SEQ ID NOs: 3, 29 and 45; and a light chain variable region comprising a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence selected from SEQ ID NOs: 4, 30 and 46, LCDR2 comprises an amino acid sequence selected from SEQ ID NOs: 5, 31 and 47, and LCDR3 comprises an amino acid sequence selected from SEQ ID NOs: 6, 32 and 48, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0041] In one aspect, disclosed herein is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising: a heavy chain variable region comprising the amino acid sequence listed in SEQ ID NO: 7, 9, 33 or 49; and a light chain variable region comprising the amino acid sequence listed in SEQ ID NO: 11, 35 or 51, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0042] In one aspect, disclosed herein is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising an amino acid sequence set forth in SEQ ID NO: 13, 15, 17, 37 or 53.
[0043] In some embodiments, specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (eg, canine programmed death-ligand 1).
[0044] In one aspect, disclosed herein is a bispecific molecule comprising an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein linked to a molecule having a second binding specificity.
[0045] In one aspect, disclosed herein is an immunoconjugate comprising an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, or a bispecific molecule described herein, linked to a therapeutic agent.
[0046] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein.
[0047] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region encoded by a nucleic acid comprising a polynucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and a light chain variable region encoded by a nucleic acid comprising a polynucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52;
[0048] In some embodiments, the heavy chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34, or 50. In some embodiments, the light chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 12, 36, or 52.
[0049] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO:8; and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO:12.
[0050] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 10; and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 12.
[0051] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 34; and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 36.
[0052] In one aspect, disclosed herein is an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof, comprising: a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 50; and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO: 52.
[0053] In some embodiments, the antibody or its antigen-binding fragment is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these. In some embodiments, the antibody or its antigen-binding fragment is selected from a full-length antibody, Fab, a single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a diabody. In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody is a dog or caninized antibody. In some embodiments, the antibody is a dog antibody.
[0054] In one aspect, disclosed herein is an isolated nucleic acid encoding a single-chain variable fragment (scFv), comprising: a heavy chain variable region comprising a nucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and a light chain variable region comprising a nucleotide sequence set forth in SEQ ID NO: 12, 36 or 52, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0055] In one aspect, disclosed herein is an isolated nucleic acid encoding a single-chain variable fragment (scFv) comprising a polynucleotide sequence set forth in SEQ ID NO: 14, 16, 18, 38 or 54.
[0056] In some embodiments, the antibody or antigen-binding fragment thereof or scFv specifically binds to canine programmed death protein 1 (cPD-1). In some embodiments, the specific binding of the antibody or antigen-binding fragment thereof or scFv to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0057] In one aspect, disclosed herein is a vector comprising an isolated nucleic acid described herein. In some embodiments, the vector is an expression vector. In some embodiments, the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, and a retroviral vector.
[0058] In one aspect, disclosed herein is a host cell comprising an isolated nucleic acid described herein or a vector described herein. In some embodiments, the host cell is of eukaryotic or prokaryotic origin. In some embodiments, the host cell is of mammalian origin. In some embodiments, the host cell is of bacterial origin. In some embodiments, the host cell is a Chinese hamster ovary cell.
[0059] In one aspect, disclosed herein is a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or an scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, and a pharmaceutically acceptable excipient, carrier, or diluent. In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intratumoral administration.
[0060] In one aspect, disclosed herein is a kit comprising an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, an immunoconjugate described herein, or a pharmaceutical composition described herein, and instructions for use.
[0061] In one aspect, disclosed herein is a method of increasing T cell proliferation and reducing T cell exhaustion in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, an immunoconjugate described herein, or a pharmaceutical composition described herein.
[0062] In one aspect, disclosed herein is a method of increasing IFNγ production in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, an immunoconjugate described herein, or a pharmaceutical composition described herein.
[0063] In one aspect, disclosed herein is a method of inhibiting the canine programmed death protein 1 (cPD-1) signaling pathway in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, an immunoconjugate described herein, or a pharmaceutical composition described herein.
[0064] In some embodiments, the subject has cancer, sepsis or septic shock, or a chronic infection (eg, a viral infection).
[0065] In one aspect, disclosed herein is a method of treating a disease or condition in a subject in need thereof, comprising administering an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, an immunoconjugate described herein, or a pharmaceutical composition described herein. In some embodiments, the disease or condition comprises cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection). In some embodiments, the method further comprises administering one or more additional therapies (e.g., chemotherapy) or interventions.
[0066] In some embodiments, the cancer is associated with the canine programmed death protein 1 (cPD-1) signaling pathway. In some embodiments, a ligand for cPD-1 (e.g., canine programmed death ligand 1) is expressed on a cancer cell of a subject. In some embodiments, cPD-1 is expressed on an immune cell of a subject. In some embodiments, the immune cell comprises a T cell (e.g., an activated T cell), a B cell, a natural killer (NK) cell, a regulatory T cell, a macrophage, or a dendritic cell (DC). In some cases, the immune cell comprises an activated T cell. In some cases, the immune cell comprises a tumor infiltrating lymphocyte. In some embodiments, the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone, gallbladder cancer, or bile duct cancer. , Gestational Trophoblastic Disease, Germ Cell Tumor, Hematological Malignancies, Hepatocellular Carcinoma, Islet Cell Tumor, Kaposi's Sarcoma, Kidney Cancer, Lipoma / Benign Lipoma, Liposarcoma / Malignant Lipoma, Medulloblastoma, Meningioma, Merkel Cell Carcinoma, Multiple Endocrine Neoplasia, Multiple Myeloma, Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Tumor, Papillary Thyroid Carcinoma, Parathyroid Tumor, Pediatric Cancer, Peripheral Nerve Sheath Tumor, Pheochromocytoma, Pituitary Tumor, Prostate Cancer, Posterior Uveal Melanoma, Rare Hematological Disorders, Metastatic Kidney Cancer, Rhabdoid Tumor, Rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Gastric Cancer, Synovial Sarcoma, Testicular Cancer, Thymic Cancer, Thymoma, Thyroid Metastasis, Uterine Cancer, or any combination thereof. In some embodiments, the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer, and neck cancer.
[0067] In some embodiments, the antibody or antigen-binding fragment thereof, canine antibody, scFv, bispecific molecule, or immunoconjugate specifically binds to cPD-1. In some embodiments, the binding of the antibody or antigen-binding fragment thereof, canine antibody, scFv, bispecific molecule, or immunoconjugate to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1). In some embodiments, the subject is a dog.
[0068] In one aspect, disclosed herein is a method of making a pharmaceutical composition described herein, comprising mixing an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein and a pharmaceutically acceptable excipient, carrier, or diluent.
[0069] In one aspect, disclosed herein is a method of making a composition for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection), comprising mixing an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, and a pharmaceutically acceptable excipient, carrier, or diluent. In some embodiments, the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone, gallbladder cancer, or bile duct cancer. , Gestational Trophoblastic Disease, Germ Cell Tumor, Hematological Malignancies, Hepatocellular Carcinoma, Islet Cell Tumor, Kaposi's Sarcoma, Kidney Cancer, Lipoma / Benign Lipoma, Liposarcoma / Malignant Lipoma, Medulloblastoma, Meningioma, Merkel Cell Carcinoma, Multiple Endocrine Neoplasia, Multiple Myeloma, Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Tumor, Papillary Thyroid Carcinoma, Parathyroid Tumor, Pediatric Cancer, Peripheral Nerve Sheath Tumor, Pheochromocytoma, Pituitary Tumor, Prostate Cancer, Posterior Uveal Melanoma, Rare Hematological Disorders, Metastatic Kidney Cancer, Rhabdoid Tumor, Rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Gastric Cancer, Synovial Sarcoma, Testicular Cancer, Thymic Cancer, Thymoma, Thyroid Metastasis, Uterine Cancer, or any combination thereof. In some embodiments, the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer, and neck cancer.
[0070] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, or a pharmaceutical composition described herein for use as a medicament.
[0071] In one aspect, disclosed herein is an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, or a pharmaceutical composition described herein, for use as a medicament for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0072] In one aspect, disclosed herein is the use of an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, or a pharmaceutical composition described herein for the manufacture of a medicament.
[0073] In one aspect, disclosed herein is the use of an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, a bispecific molecule described herein, or an immunoconjugate described herein, or a pharmaceutical composition described herein for the manufacture of a medicament for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0074] In one aspect, disclosed herein is a method of producing an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein, or a bispecific molecule described herein, comprising culturing a host cell described herein. In some embodiments, the method further comprises incubating a host cell described herein in a cell culture medium under conditions sufficient to allow expression and secretion of an antibody or antigen-binding fragment thereof described herein, a canine antibody described herein, or a scFv described herein.
[0075] Incorporated by Reference
[0076] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] The following detailed description of the preferred embodiments of the present disclosure will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present disclosure, there are shown in the accompanying drawings presently preferred embodiments. However, it should be understood that the present disclosure is not limited to the precise arrangements and means of the embodiments shown in the accompanying drawings.
[0078] Figure 1The enrichment of canine scFv phage display library after panning against canine PD-1 antigen is illustrated. Recombinant canine PD-1 was adsorbed to microplates overnight at 4°C. The wells were rinsed and blocked with 2% milk in PBS (MPBS) for 1 hour at 37°C. The initial unpanned library (P0) and the phage library obtained after each round of selection (P1 to P4) were added to the coated plate and incubated at 37°C for 1 hour. The plate was rinsed with PBS supplemented with 0.1% Tween (PBST), and bound phages were detected using a 1:5000 dilution of HRP-conjugated anti-M13 mAb in MPBS. The bound anti-M13 mAb was detected with ABTS substrate. The OD value was read at 405nm using a Molecular Devices SpectraMax 340 spectrophotometer after 30 minutes.
[0079] Figure 2A-2B Binding of randomly selected scFv-expressing phage clones from the third and fourth rounds of panning to canine PD-1 is illustrated. Polyclonal phage from the fourth round of panning against cPD-1 served as positive controls in cases where wells were coated with cPD-1 and as negative controls in cases where wells were coated with human (h)CD19 ( Figure 2A In an unrelated study, polyclonal phage from the third round of panning against hCD19 were used as positive controls in cases where wells were coated with hCD19 and as negative controls in cases where wells were coated with cPD-1 ( Figure 2A ).exist Figure 2B In the Figure 3, polyclonal phage from the fourth round of panning against canine (c)IL13Ra2 in an unrelated study and wells coated with cPD-1 and cIL13Ra2 were similarly used as negative and positive controls, respectively.
[0080] Figure 3 The ability of unique soluble scFv clones to bind to cPD-1 was illustrated by ELISA. 19 unique soluble scFvs were tested for binding to cPD-1 by ELISA. Increasing amounts of biotinylated canine PD-1 were captured on ELISA plates coated with streptavidin (SA). 0.25 μg / ml soluble hemagglutinin (HA)-tagged scFvs were added to the wells, and bound scFvs were detected using AP-conjugated anti-HA antibodies. An unrelated soluble HA-tagged scFv from a different project targeting the MERS (Middle East Respiratory Syndrome) antigen was used as a negative control.
[0081] Figure 4Diagram of the PD-1:PD-L1 inhibition assay. ELISA plates were coated with streptavidin. Soluble biotinylated canine PD-1 was incubated with increasing concentrations of canine PD-L1-Fc alone or in the presence of selected soluble anti-PD-1 scFv or an irrelevant soluble scFv against MERS. The pre-incubated mixture was added to the ELISA plate and the binding of PD-L1 to PD-1 was detected using an anti-Fc-AP conjugate. Boxed and numbered clones inhibited the PD-1:PD-L1 interaction.
[0082] Figure 5 Figure 3. Binding of soluble canine anti-PD-1 scFv to cell surface expressed PD-1. The scaffold human erythroleukemia cell line K562 was gene edited to eliminate FcγRII (CD32) (KTδ32). The edited cells were retrovirally transduced to express cPD-1, and PD-1 positive target cells were selected in puromycin. Soluble, purified, HA-tagged scFv was incubated with target cells, and bound scFv was detected using anti-HA antibody. Soluble scFvs from anti-MERS and clone 3-7, which showed low affinity binding to cPD-1 by ELISA, were used as negative controls.
[0083] Figure 6 Illustration of the binding of whole canine anti-PD-1 IgG4 to cell surface expressed PD-1 assessed by flow cytometry. KTδ32 cells were retrovirally transduced to express cPD-1 and target-positive cells were selected using puromycin. KTδ32 and KTδ32.cPD-1 were stained with whole canine IgG4-HA-tagged clones against canine PD-1 or an irrelevant MERS antibody. Bound IgG4 molecules were detected using anti-HA antibodies.
[0084] Figure 7 Figure 3. Binding of P3C6 antibody mutants to cPD-1. P3C6 was selected for further development and testing based on functional assays and cell surface binding. Mutations were introduced in framework regions to improve yield / developability of P3C6. Full-length IgG was produced and mutants were tested for their ability to bind to soluble cPD-1 by ELISA. P3C6mut3.1 and P3C6mut3.2, derived from the parental P3C6 clone, have 4 and 5 amino acid substitutions, respectively, with only one amino acid difference between the mutant sequences. P4B1 and P4-14 were used as positive controls.
[0085] Figure 8The binding of P3C6 antibody mutants to cPD-1 is illustrated. KTδ32 cells were retrovirally transduced to express cPD-1, and target-positive cells were selected using puromycin. Cells were labeled with two P3C6 mutants (mut3.1 and mut3.2) or P4B1 to confirm binding to PD-1 expressed on the cell surface. Bound antibodies were detected using anti-HA antibodies. An unrelated anti-MERS antibody was used as a negative control. The figure is gated for live 7AAD- cells.
[0086] Figures 9A-9B The production of P3C6 antibody mutants by transient transfection of 293T cells is shown.
[0087] Fig.10 Figure 3. P3C6 mutant antibody enhances the proliferation capacity of canine T cells. Canine PBMCs were labeled with cell trace violet (CTV) and stimulated with 2.5 μg / ml concanavalin A in the presence of P4B1, P3C6 (mut3.1 and mut3.2) full-length IgG or an irrelevant MERS control antibody. Cells were labeled with anti-CD5 antibody and analyzed by flow cytometry at 96 hours. The figure is gated for live CD5+ cells. Data for one dog are shown. Cells showed enhanced proliferation capacity and predicted fold expansion when stimulated in the presence of anti-PD-1 IgG compared to MERS antibodies.
[0088] Fig.11 The P3C6 IgG4 mutant promotes IFN-γ production by mitogen-activated canine T cells. Canine PBMCs were stimulated with 2.5 mg / ml concanavalin A in the presence of P4B1, P3C6 (mut3.1 and mut3.2) IgG4 or an unrelated MERS antibody. Supernatants were collected after 96 hours and the presence of IFN-γ was determined by ELISA. Data from two dogs are shown. Both P3C6 mutants showed increased IFN-γ production compared to anti-MERS antibodies and a second anti-PD-1 clone (P4B1).
[0089] Fig.12Binding of clone A6 to cell surface cPD-1 is illustrated. KTδ32 and KTδ32.cPD-1 cells were labeled with two P3C6 mutants (mut3.1 and mut3.2) or clone A6 reformatted as IgG4 to confirm binding to cPD-1 expressed on the cell surface. Bound antibodies were detected using anti-HA antibodies. Antibodies against an irrelevant MERS virus antigen were used as negative controls. The figure is gated for live 7AAD- cells. Where indicated, clones were pre-incubated with soluble cPD-1 to block antigen binding sites. Pre-blocking resulted in a loss of binding of clone A6 and a reduction in cell surface labeling of clones P3C6 mut 3.1 and 3.2. DETAILED DESCRIPTION
[0090] Canine antibody phage display libraries can be used to identify antigen-specific single-chain variable fragment (scFv) fusion proteins that specifically bind to canine programmed death protein 1 (cPD-1). These canine PD-1-specific scFvs can then be converted into full-length antibodies that include canine constant regions, making them suitable for use in canine subjects. Full canine antibodies have a lower risk of inducing an immune response in canine subjects than mouse antibodies, chimeric antibodies, or caninized antibodies. In some cases, full canine anti-PD-1 can be non-immunogenic and effective in inhibiting checkpoints when treating canine cancer patients. Incorporating this full canine anti-canine PD-1 antibody therapy into a veterinary arsenal may improve treatment outcomes for pet dogs with malignancies.
[0091] In addition, the present disclosure may shed light on issues in human immuno-oncology. The use of whole canine anti-PD-1 in immunocompetent canine cancer patients with spontaneous tumors that have similar characteristics to human corresponding tumors may provide informative results for human clinical trial design. The development of whole canine anti-PD-1 provides an important comparative tool for translational research in human immuno-oncology and enables certain combination therapies being evaluated that include checkpoint inhibition.
[0092] The present disclosure provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1), comprising: (a) a heavy chain complementary determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, 27 or 43, (b) a heavy chain complementary determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, 28 or 44, (c) a heavy chain complementary determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, 29 or 45, (d) a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, 30 or 46, (e) a light chain complementary determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, 31 or 47, and (f) a light chain complementary determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 6, 32 or 48.
[0093] In some aspects, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1), comprising: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 11, 35 or 51.
[0094] In some aspects, disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1), comprising: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 19, 21, 23, 39 or 55, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence listed in SEQ ID NO: 25, 41 or 57.
[0095] In some aspects, provided herein is a canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1).
[0096] In some aspects, provided herein is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising: (a) a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2 and HCDR3, wherein HCDR1 comprises an amino acid sequence selected from SEQ ID NOs: 1, 27 and 43, HCDR2 comprises an amino acid sequence selected from SEQ ID NOs: 2, 28 and 44, and HCDR3 comprises an amino acid sequence selected from SEQ ID NOs: 3, 29 and 45; and (b) a light chain variable region comprising a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence selected from SEQ ID NOs: 4, 30 and 46, LCDR2 comprises an amino acid sequence selected from SEQ ID NOs: 5, 31 and 47, and LCDR3 comprises an amino acid sequence selected from SEQ ID NOs: 6, 32 and 48, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0097] In some aspects, provided herein is a single-chain variable fragment (scFv) comprising: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0098] In some aspects, provided herein is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising an amino acid sequence set forth in SEQ ID NO: 13, 15, 17, 37 or 53.
[0099] Also provided are the bispecific molecules, immunoconjugates, nucleic acids, vectors, host cells, kits, compositions of antibodies and antigen-binding fragments specific for canine PD-1 or scFv described herein, and methods of producing and using the same for treating cancer in a subject (e.g., a canine subject).
[0100] definition
[0101] In the detailed description, certain specific details are explained to provide a thorough understanding of various embodiments. However, those skilled in the art will understand that the embodiments provided can be implemented without these details. Unless the context otherwise requires, throughout the specification and claims, the word "comprise" and its variations, such as "comprises" and "comprising" should be understood as open and inclusive, that is, "including, but not limited to". Unless the content clearly stipulates otherwise, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural references. It should also be noted that the term "or" is generally intended to include the meaning of "and / or", unless the content clearly stipulates otherwise. In addition, the headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.
[0102] The articles "a" and "an" are used herein to refer to one or more (ie, to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0103] As used herein, the term "about" refers to an amount that is close to 10% or less of the amount. As used herein, the term "individual," "patient," or "subject" refers to an individual diagnosed with, suspected of having, or at risk of suffering from at least one disease that the described compositions and methods can be used to treat. In certain embodiments, the individual is a mammal. In certain embodiments, the mammal is a mouse, rat, rabbit, dog, cat, horse, cow, sheep, pig, goat, llama, alpaca, or yak. In certain embodiments, the individual is a dog or canine.
[0104] As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to an antigen. An antibody can be a complete immunoglobulin derived from a natural source or a recombinant source, and can be an immunologically active portion of a complete immunoglobulin. An antibody is typically a tetramer of an immunoglobulin molecule comprising two heavy chains and two light chain polypeptides. Each polypeptide chain contains three complementary determining regions (CDRs) that bind to an antigen and define the antigen specificity of the antibody.
[0105] As used herein, the terms "antibody" and "antibodies" may also include polypeptides or polypeptide complexes derived from full-length antibodies. These polypeptide complexes may be naturally occurring, or may be constructed from single-chain antibodies or antibody fragments and retain antigen-specific binding capabilities. The antibodies of the present disclosure may exist in a variety of forms, including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab, and F(ab'). 2, as well as single-chain antibodies, scFvs, caninized antibodies, canine antibodies, humanized antibodies and human antibodies (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al. 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). To prepare suitable antibodies, e.g., recombinant antibodies, monoclonal antibodies or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler & Milstein, Nature 256: 495-497 (1975); Kozbor et al. Immunology Today 4: 72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2nd edition, 1986)). Genes encoding the heavy and light chains of an antibody of interest can be cloned from cells, e.g., genes encoding monoclonal antibodies can be cloned from hybridomas, and used to produce recombinant monoclonal antibodies. The gene library of the heavy chain and light chain of encoding monoclonal antibody can also be made from hybridoma or plasma cell. The random combination of heavy chain and light chain gene products produces a large number of antibodies with different antigen specificity (see, e.g., Kuby, Immunology (3rd edition, 1997)). The technology of producing single-chain antibody or recombinant antibody (U.S. Patent No.: 4,946,778, 4,816,567) can be used to produce the antibody of the present disclosure.In addition, transgenic mice or other organisms, such as other mammals, can be used to express humanized or human antibodies as well as caninized or canine antibodies (see, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, Marks et al., Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); and Lonberg & Huszar, Intern. Rev. Immunol. 13: 65-93 (1995)). Alternatively, phage display technology can also be used to identify antibodies and heterologous Fab fragments that specifically bind to a selected antigen (see, e.g., McCafferty et al., Nature 348: 552-554 (1990); Marks et al., Biotechnology 10: 779-783 (1992)). Antibodies can also be made bispecific, i.e., capable of recognizing two different antigens (see, e.g., WO 93 / 08829, Traunecker et al., EMBO J. 10: 3655-3659 (1991); and Suresh et al., Methods in Enzymology 121: 210 (1986)). The antibody may also be a heteroconjugate, eg, two covalently linked antibodies or immunotoxins (see, eg, US Pat. No. 4,676,980, WO 91 / 00360; WO 92 / 200373; and EP 03089).
[0106] As used herein, molecules, peptides, polypeptides, antibodies or antibody fragments may be referred to as "bispecific" or "dual-specific", including grammatical equivalents. Bispecific molecules have the ability to specifically bind to at least two structurally different targets. The specific binding may be the result of two different binding moieties that are structurally different at the molecular level, including but not limited to different non-identical amino acid sequences; or the ability to bind to a target with high affinity (e.g., less than about 1x10 -6A single binding portion that specifically binds to two structurally different targets (KD) with a KD of 1.5. The molecules, peptides, polypeptides, antibodies or antibody fragments referred to as "multi-specific" are molecules that have the ability to specifically bind to at least three structurally different targets. "Bispecific antibodies", including grammatical equivalents, refer to bispecific molecules that retain at least one antibody fragment that can specifically bind to a target, such as a variable region, heavy chain or light chain, or one or more complementary determining regions from an antibody molecule. "Multi-specific antibodies", including grammatical equivalents, refer to multispecific molecules that retain at least one antibody fragment that can specifically bind to a target, such as a variable region, heavy chain or light chain, or complementary determining region from an antibody molecule.
[0107] "Linker" herein is also referred to as "linker sequence", "spacer", "tethering sequence" or its grammatical equivalent. The "linker" mentioned herein connects two different molecules, which themselves have target binding ability, catalytic activity, or are naturally expressed and assembled into independent polypeptides, or include separate domains of the same polypeptide. For example, two different binding moieties or a pair of heavy chain / light chain. A variety of strategies can be used to covalently link molecules together. The linkers described herein can be used to connect the light chain variable region and the heavy chain variable region in the scFv molecule; or to tie the scFv or other antigen binding fragment to the N- or C-terminus of the antibody heavy chain; or the N- or C-terminus of the light chain to create a bispecific or multispecific binding molecule. These include, but are not limited to, polypeptide connections between the N-terminus and the C-terminus of a protein or protein domain, connections via disulfide bonds, and connections by chemical cross-linking agents. In one aspect of this embodiment, the linker is a peptide bond produced by recombinant technology or peptide synthesis. The linker peptide may mainly include the following amino acid residues: Gly, Ser, Ala or Thr. The joint peptide should have a length that is enough to connect two molecules so that it has correct conformation relative to each other, thereby maintaining the required activity. In one embodiment, the length of the joint is about 1 to 50 amino acid, or about 1 to 30 amino acid. In one embodiment, a joint of 1 to 20 amino acid in length can be used. Useful joints include glycine-serine polymers (including, for example, (GS) n, (GSGGS) n (SEQ ID NO:65), (GGGGS) n (SEQ ID NO:67) and (GGGS) n (SEQ ID NO:66), wherein n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers and other flexible joints. Exemplary joints for connecting antibody fragments or single-chain variable fragments may include AAEPKSS (SEQ ID NO:78), AAEPKSSDKTHTCPPCP (SEQ ID NO:79), GGGG (SEQID NO:80) or GGGGDKTHTCPPCP (SEQ ID NO:81). Alternatively, various non-protein polymers, including but not limited to polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylene, or copolymers of polyethylene glycol and polypropylene glycol, can also be used as linkers.
[0108] The terms "complementarity determining region" and "CDR" are synonymous with "hypervariable region" or "HVR", and are known in the art to refer to non-contiguous amino acid sequences within an antibody variable region that confer antigen specificity and / or binding affinity. Generally, there are three CDRs (CDR-H1, CDR-H2, CDR-H3) in each heavy chain variable region, and three CDRs (CDR-L1, CDR-L2, CDR-L3) in each light chain variable region. "Framework region" and "FR" are known in the art to refer to the non-CDR portions of the heavy and light chain variable regions. Generally, there are four FRs (FR-H1, FR-H2, FR-H3, and FR-H4) in each full-length heavy chain variable region, and four FRs (FR-L1, FR-L2, FR-L3, and FR-L4) in each full-length light chain variable region.The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known methods, including those described in Kabat et al., (1991), "Sequences of Proteins of Immunological Interest", 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography", J. Mol. Biol. 262, 732-745. ("Contact" numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", DevComp Immunol, 2003 Jan; 27 (1): 55-77 ("IMGT" numbering scheme); Honegger A and Plückthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J Mol Biol, 2001 Jun 8; 309 (3): 657-70, ("Aho" numbering scheme); and Whitelegg NR and Rees AR, "WAM: an improved algorithm for modelling antibodies on the WEB", Protein Eng. 2000 Dec; 13 (12): 819-24 ("AbM" numbering scheme). In certain embodiments, the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or a combination thereof.
[0109] The boundaries of a given CDR or FR will vary with the scheme used for identification. For example, the Kabat scheme is based on structural arrangement, and the Chothia scheme is based on structural information. The numbering of both the Kabat and Chothia schemes is based on the most common antibody region sequence length, with insertions represented by inserted letters, such as "30a", and deletions occurring in some antibodies. These two schemes place certain insertions and deletions ("indels") in different positions, resulting in different numbering. The Contact scheme is based on the analysis of complex crystal structures, and is similar to the Chothia numbering scheme in many respects. In some embodiments, the CDR of an antibody described herein can be defined by the IMGT method.
[0110] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen. H and V L ) generally have similar structures, each domain comprising four conserved framework regions (FRs) and three CDRs (see, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and co-authors, p. 91 (2007)). A single V H or V L The domain is sufficient to confer antigen binding specificity. In addition, V H or V L The domain is separated from the antibody that binds the specific antigen to screen for complementary V L or V H Domain repertoires (see, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991)).
[0111] The specific binding or binding of the antibody molecules described herein refers to the binding mediated by one or more CDR portions of the antibody. Specific binding does not necessarily require all CDRs. Specific binding can be demonstrated, for example, by ELISA for a specific target or antigen, which shows a significant increase in binding compared to an isotype control antibody.
[0112] "Epitope" refers to the binding determinant of the antibody or antibody fragment described herein that is minimally required for the antibody or fragment to specifically bind to the target antigen. When the target antigen is a polypeptide, the epitope will be a continuous or discontinuous epitope. A continuous epitope is formed by one region of the target antigen, while a discontinuous epitope may be formed by two or more independent regions. For example, a discontinuous epitope is formed when the target antigen adopts a tertiary structure that binds two amino acid sequences together and forms a three-dimensional structure bound by the antibody. When the target antigen is a polypeptide, the epitope is usually a plurality of amino acids connected into a polypeptide chain. A continuous epitope may include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 consecutive amino acids. Although an epitope may include a continuous amino acid polymer, not every amino acid in the polymer can be contacted by the amino acid residues of the antibody. Such non-contacting amino acids will still constitute part of the epitope because they may be important for the structure and connection of the contacting amino acids. A skilled person can determine whether any given antibody binds to an epitope of a reference antibody by, for example, a cross-blocking experiment with a reference antibody. In certain embodiments, antibodies are described herein that bind to the same epitope as the described antibodies. In certain embodiments, antibodies are described herein that can be competitively blocked by the described antibodies. In certain embodiments, antibodies are described herein that competitively bind to the described antibodies.
[0113] The term "antibody fragment" refers to a polypeptide that comprises a portion of an intact antibody or is derived from a portion thereof and includes the antigen binding determining variable region of the intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab') 2 And Fv fragments, linear antibodies, scFv antibodies, single domain antibodies such as camelid antibodies (Riechmann, 1999, Journal of Immunological Methods 231: 25-38) (consisting of VL or VH domains that exhibit sufficient affinity for the target) and multispecific antibodies formed by antibody fragments. Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells. In some embodiments, the antibody is a recombinantly produced fragment, such as a fragment comprising a non-naturally occurring arrangement, such as a fragment having two or more antibody regions or antibody chains connected by a synthetic linker (e.g., a polypeptide linker), and / or a fragment that is not produced by enzymatic digestion of a naturally occurring intact antibody. In some aspects, the antibody fragment is a scFv.
[0114] Fab or Fab fragments contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' or Fab' fragments differ from Fab fragments in that a few residues are added to the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the hinge region of the antibody. Fab' fragments are produced by cleaving the disulfide bonds at the hinge cysteines of the F(ab')2 pepsin digestion product. Other chemical couplings of antibody fragments are known to those of ordinary skill in the art. Fab and F(ab')2 fragments lack the fragment crystallizable (Fc) region of the complete antibody, are cleared from the blood circulation of the animal more quickly, and have lower non-specific tissue binding than complete antibodies. The "Fv" fragment is the smallest fragment containing a complete target recognition and binding site in an antibody. This region consists of a dimer (VH-VL dimer) of a heavy chain variable domain and a light chain variable domain in tight, non-covalent association. Its configuration is such that the three CDRs of each variable domain interact to define a target binding site on the surface of the VHVL dimer. In some cases, six CDRs confer specificity to an antibody for binding to a target. However, in some cases, even a single variable domain (or half of an Fv comprising only three target-specific CDRs) has the ability to recognize and bind to a target. Single domain antibodies (sdAbs) / single chain fragments consist of a single VH or VL domain that exhibits sufficient affinity for an antigen. Antibody fragments also include canine antibodies or caninized antibodies or a portion of a canine antibody or caninized antibody. scFv (single-chain Fv) refers to an antibody binding fragment comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In general, the scFv polypeptide further includes a polypeptide linker between the VH and VL domains that enables the scFv to form a structure that is conducive to target binding.
[0115] The term "diabody" refers to a small antibody fragment prepared by constructing an scFv fragment with a short linker (about 5-10 residues) between the VH and VL domains, so that interchain pairing of the variable domains is achieved rather than intrachain pairing, resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. A bispecific diabody is a heterodimer of two "crossover" scFv fragments, in which the VH and VL domains of the two antibodies are present on different polypeptide chains.
[0116] The term "linear antibody" generally refers to an antibody comprising a pair of tandem Fd fragments (VH-CH1-VH-CH1), which together with complementary light chain polypeptides form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
[0117] As used herein, "antibody heavy chain" refers to the larger of the two polypeptide chains present in all antibody molecules in their naturally occurring conformation.
[0118] As used herein, "antibody light chain" refers to the smaller of the two polypeptide chains present in all antibody molecules in their naturally occurring conformations. Kappa and lambda light chains refer to the two major antibody light chain isotypes.
[0119] As used herein, the term "synthetic antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage as described herein. The term should also be understood to refer to an antibody produced by synthesizing a DNA molecule encoding the antibody, and the DNA molecule expresses the antibody protein or specifies the amino acid sequence of the antibody, wherein the DNA or amino acid sequence is obtained using synthetic DNA or amino acid sequence technology available in the art and well known.
[0120] The term "antigen" or "Ag" as used herein is defined as a molecule that causes an immune response. This immune response may involve the production of antibodies, or the activation of specific immunologically competent cells, or both. It will be understood by the skilled person that any macromolecule, including substantially all proteins or peptides, can be used as an antigen. In addition, antigens can be derived from recombinant DNA or genomic DNA. Therefore, it will be understood by the skilled person that any DNA including a nucleotide sequence or a partial nucleotide sequence encoding a protein that causes an immune response encodes the term "antigen" as used herein. In addition, it will be understood by those skilled in the art that antigens do not necessarily have to be encoded only by the full-length nucleotide sequence of a gene. It is readily apparent that the present disclosure includes, but is not limited to, using partial nucleotide sequences of more than one gene, and that these nucleotide sequences are arranged in various combinations to cause a desired immune response. In addition, it will be understood by the skilled person that antigens do not need to be encoded by a "gene" at all. It is readily apparent that antigens can be produced synthetically or can be derived from a biological sample. Such a biological sample can include, but is not limited to, a tissue sample, a tumor sample, a cell, or a biological fluid.
[0121] As used herein, the term "anti-tumor effect" refers to a biological effect that is manifested as a reduction in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastatic lesions, an increase in life expectancy, or an improvement in various physiological symptoms associated with a cancer disorder. "Anti-tumor effect" can also be manifested as the ability of the peptides, polynucleotides, cells and antibodies of the present disclosure to prevent the appearance of tumors at the initial location.
[0122] As used herein, the term "autologous" refers to any material derived from the same individual that is subsequently reintroduced into that individual.
[0123] "Allogeneic" refers to a transplant derived from a different animal of the same species.
[0124] "Xenogeneic" refers to a transplant that originates from an animal of a different species.
[0125] As used herein, the term "cancer" refers to a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or to other parts of the body through the blood and lymphatic system. Examples of various cancers include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc. In certain embodiments, the cancer is medullary thyroid cancer.
[0126] As used herein, the term "conservative sequence modification" refers to an amino acid modification that does not significantly affect or change the binding properties of an antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are amino acid substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, one or more amino acid residues within the CDR region of an antibody of the present disclosure can be substituted with other amino acid residues of the same side chain family, and the ability of the altered antibody to bind to GFRα4 can be tested using the functional assays described herein.
[0127] As used herein, "costimulatory ligands" include molecules expressed by antigen presenting cells (e.g., aAPCs, dendritic cells, B cells, etc.) that specifically bind to cognate costimulatory molecules on T cells, thereby providing signals that mediate T cell responses including, but not limited to, proliferation, activation, differentiation, etc., in addition to the primary signal provided by, for example, the binding of the TCR / CD3 complex to the MHC molecule loaded with the peptide. Costimulatory ligands may include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible co-stimulatory ligand (ICOS-L), intercellular adhesion molecules (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonists or antibodies that bind to Toll ligand receptors, and ligands that specifically bind to B7-H3. Co-stimulatory ligands also include antibodies that specifically bind to co-stimulatory molecules present on T cells, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40L, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.
[0128] "Co-stimulatory molecules" refer to cell surface molecules expressed by T cells that specifically bind to co-stimulatory ligands expressed by antigen presenting cells (APCs), thereby providing a "secondary signal" that is combined with the "primary signal" transmitted by the interaction of MHC / HLA-antigens with T cell receptors (TCRs), resulting in optimal T cell activation, including but not limited to the production and proliferation of cytokines. Co-stimulatory molecules include but are not limited to CD27, CD28, 4-1BB, OX40, CD30, CD40L, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.
[0129] When used in the context of the expression level or activity of PD-1 or its ligands (PD-L1 and PD-L2), the term "dysregulated" refers to an expression level or activity that is different from the expression level or activity of PD-1 or its ligands in an otherwise identical healthy animal, organism, tissue, cell, or component thereof. The term "dysregulated" also refers to altered regulation of the expression level and activity of PD-1, PD-L1 compared to regulation in an otherwise identical healthy animal, organism, tissue, cell, or component thereof.
[0130] "Encoding" refers to the intrinsic properties of a specific nucleotide sequence in a polynucleotide such as a gene, cDNA or mRNA used as a template for synthesizing other polymers and macromolecules in a biological process, and the polymer or macromolecule has a defined nucleotide sequence (i.e., rRNA, tRNA and mRNA) or a defined amino acid sequence, and the resulting biological properties. Therefore, if the transcription and translation of the mRNA corresponding to the gene produce a protein in a cell or other biological system, the gene encodes the protein. Both the coding strand and the non-coding strand can be referred to as proteins or other products encoding the gene or cDNA, the nucleotide sequence of the coding strand is identical to the mRNA sequence and is usually provided in the sequence table, and the non-coding strand is used as a template for gene or cDNA transcription.
[0131] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins and RNA may include introns.
[0132] "Effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, material or composition as described herein that is effective to achieve a specific biological result. Such results may include, but are not limited to, inhibition of viral infection as determined by any suitable means in the art.
[0133] As used herein, "endogenous" refers to any material that originates from or is produced within an organism, cell, tissue, or system.
[0134] As used herein, the term "exogenous" refers to any material that is introduced from or produced outside of an organism, cell, tissue, or system.
[0135] As used herein, the term "expression" is defined as the transcription and / or translation of a specific nucleotide sequence driven by its promoter.
[0136] "Expression vector" refers to a vector comprising a recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence to be expressed. The expression vector comprises sufficient cis-acting elements for expression; other elements for expression may be supplied by the host cell or in an in vitro expression system. Expression vectors include all vectors known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses and adeno-associated viruses), which incorporate a recombinant polynucleotide.
[0137] As used herein, "homologous" refers to the subunit sequence identity between two polymer molecules, such as two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. When the positions of both subunits in the two molecules are occupied by the same monomer subunit; for example, if the position of each molecule in the two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matches or homologous positions; for example, if half of the positions in the two sequences (e.g., five positions in a polymer of ten subunits in length) are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous.
[0138] "Humanized" or "caninized" and "chimeric" forms of non-human or non-canine (e.g., mouse) antibodies are immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human or non-canine immunoglobulins. In most cases, humanized, caninized, and chimeric antibodies are human or canine immunoglobulins (recipient antibodies) in which residues from the complementary determining regions (CDRs) of the recipient's antibodies are replaced by residues from CDRs of non-human or non-canine species (such as mouse, rat, or rabbit) having the desired specificity, affinity, and capacity (donor antibody). In some cases, Fv framework region (FR) residues of the human or canine immunoglobulin are replaced by corresponding non-human or non-canine residues. In addition, humanized, caninized, and chimeric antibodies may also include residues that are neither present in the recipient antibody nor in the imported CDR or framework sequences. These modifications are intended to further refine and optimize the performance of the antibodies. In general, humanized, caninized and chimeric antibodies will include substantially all of at least one (and typically two) variable domains, in which all or substantially all of the CDR regions correspond to the variable domains of a non-human immunoglobulin, and all or substantially all of the FR regions are variable domains of human or canine immunoglobulin sequences. Caninized and chimeric antibodies will also optimally include at least a portion of an immunoglobulin constant region (Fc), typically a canine immunoglobulin constant region.
[0139] "Fully canine" or "canine antibody" refers to an immunoglobulin, such as an antibody, whose amino acid sequence corresponds to the amino acid sequence of an antibody produced by a canine or canine cell or a non-canine source using a canine antibody library or other canine antibody coding sequences including a canine antibody library. The term does not include caninized forms of non-canine antibodies that contain non-canine antigen binding regions, such as those where all or substantially all CDRs are non-canine. In some cases, a fully canine antibody does not include partial antibody sequences from non-canine species. Canine antibodies can be prepared by administering an immunogen to a transgenic animal that has been modified to produce a complete canine antibody or a complete antibody with a canine variable region under antigen attack. Such animals typically contain all or part of a canine immunoglobulin locus that replaces an endogenous immunoglobulin locus or exists in an extrachromosomal manner or is randomly integrated into the chromosome of the animal. In such a transgenic animal, the endogenous immunoglobulin locus is typically inactivated. Canine antibodies can also be derived from a canine antibody library including a phage display library and a cell-free library that contains antibody coding sequences from a canine gene library.
[0140] As used herein, "illustrative materials" include publications, records, charts, or any other medium of expression that can be used to convey the usefulness of the compositions and methods of the present disclosure. The illustrative materials of the kit of the present disclosure can, for example, be attached to a container containing nucleic acids, peptides, and / or compositions of the present disclosure, or be transported together with a container containing nucleic acids, peptides, and / or compositions. Alternatively, the illustrative materials can be transported separately from the container so that the illustrative materials and the compound are used in conjunction with the receptor.
[0141] As used herein, "identity" refers to the percentage of sequence identity (%) relative to a reference polypeptide sequence, which is the percentage of the amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after the sequence is aligned and, if necessary, a gap is introduced to reach the maximum percentage of sequence identity, and any conservative substitution is not used as a part of sequence identity. The comparison carried out to determine the percentage of amino acid sequence identity can be achieved by various known methods, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. The appropriate parameters for sequence alignment can be determined, including the algorithm required for achieving maximum alignment within the full length of the alignment sequence. However, for the purposes of this article, the amino acid sequence identity percentage value is generated using the ALIGN-2 sequence alignment computer program. The ALIGN-2 sequence alignment computer program is written by Genentech, Inc., and the source code has been submitted to the U.S. Copyright Office, Washington DC, 20559, together with user documentation, where it is registered with U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. in South San Francisco, California, or can be compiled from source code. The ALIGN-2 program should be compiled for use on a UNIX operating system (including digital UNIX V4.0D). All sequence alignment parameters are set by the ALIGN-2 program and will not be changed.
[0142] In the case of amino acid sequence alignment using ALIGN-2, the percentage of amino acid sequence identity of a given amino acid sequence A with or to a given amino acid sequence B (which may alternatively be expressed as a given amino acid sequence A having or including a certain percentage of amino acid sequence identity with or to a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues obtained as identical matches by the sequence alignment program ALIGN-2 in the program alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that in the case where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percentage of amino acid sequence identity of A to B will not be equal to the percentage of amino acid sequence identity of B to A. Unless specifically stated otherwise, all percentage amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.
[0143] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated," but rather the same nucleic acid or peptide is "isolated" partially or completely separated from the coexisting materials of the natural state. An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-natural environment, such as, for example, a host cell.
[0144] In the context of this disclosure, the following abbreviations are used for common nucleic acid bases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" is uridine.
[0145] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. The phrase "nucleotide sequence encoding a protein or RNA may also include introns, to the extent that some forms of protein-encoding nucleotide sequences may contain intron(s).
[0146] The term "operably linked" refers to a functional connection between a regulatory sequence and a heterologous nucleic acid sequence, resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Typically, operably linked DNA sequences are contiguous and in the same reading frame where two protein coding regions need to be joined.
[0147] "Parenteral" administration of the immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection or infusion techniques.
[0148] As used herein, the term "polynucleotide" is defined as a chain of nucleotides. In addition, nucleic acids are polymers of nucleotides. Therefore, nucleic acids and polynucleotides as used herein are interchangeable. Those skilled in the art have the common knowledge that nucleic acids are polynucleotides that can be hydrolyzed into monomeric "nucleotides". Monomeric nucleotides can be hydrolyzed into nucleosides. As used herein, polynucleotides include, but are not limited to, all nucleic acid sequences obtained by any means available in the art, including, but not limited to, recombinant means, i.e., using common cloning techniques and PCR. TM etc., and clone nucleic acid sequences from recombinant libraries or cell genomes by synthetic means.
[0149] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that make up a protein or peptide sequence. Polypeptides include any peptide or protein comprising two or more amino acids interconnected by peptide bonds. As used herein, the term refers to short chains and long chains, short chains are also commonly referred to in the art as, for example, peptides, oligopeptides and oligomers, and long chains are commonly referred to in the art as proteins, which have many types. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins, etc. Polypeptides include natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.
[0150] As used herein, the term "promoter" is defined as a DNA sequence recognized by the synthetic machinery of the cell or introduced synthetic machinery required to initiate specific transcription of a polynucleotide sequence.
[0151] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence required for the expression of a gene product that is operably linked to the promoter / regulatory sequence. In some cases, the sequence may be a core promoter sequence, while in other cases, the sequence may also include enhancer sequences and other regulatory elements required for the expression of the gene product. The promoter / regulatory sequence may be, for example, a promoter / regulatory sequence that expresses a gene product in a tissue-specific manner.
[0152] A "constitutive" promoter is a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
[0153] An "inducible" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell essentially only when an inducer corresponding to the promoter is present in the cell.
[0154] A "tissue-specific" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene, causes the gene product to be produced in a cell only if the cell is a cell of the tissue type corresponding to the promoter.
[0155] "Signal transduction pathway" refers to the biochemical relationship between various signal transduction molecules that play a role in the transmission of a signal from one part of a cell to another part of the cell. The phrase "cell surface receptor" includes molecules and complexes of molecules that are capable of receiving a signal and transmitting the signal across the plasma membrane of a cell. An example of a "cell surface receptor" is human GFRα4.
[0156] "Single chain antibody" refers to an antibody formed by recombinant DNA technology in which immunoglobulin heavy and light chain fragments are linked to each other using engineered amino acid spans to reproduce the Fv region of the antibody as a single polypeptide. Various methods for producing single chain antibodies are known, including those described in U.S. Pat. No. 4,694,778; Bird (1988) Science 242:423-442; Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; Ward et al., (1989) Nature 334:54454; Skerra et al., (1988) Science 242:1038-1041.
[0157] The term "subject" is intended to include living organisms (e.g., mammals) in which an immune response can be elicited. As used herein, a "subject" or "patient" can be a human or a non-human mammal. Non-human mammals include, for example, livestock and pets, such as sheep, cattle, pigs, dogs, cats, and murine mammals. Preferably, the subject is a dog.
[0158] As used herein, "substantially purified" cells are cells that are substantially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types that are normally associated with them in their naturally occurring state. In some cases, a substantially purified cell population refers to a homogenous cell population. In other cases, the term refers only to cells that are separated from cells that are naturally associated with them in their native state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.
[0159] As used herein, the term "therapeutic" refers to treatment and / or prevention. A therapeutic effect may be achieved by inhibiting, alleviating or eliminating the disease state.
[0160] As used herein, the term "transfected" or "transformed" or "transduced" refers to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is a cell that has been transfected, transformed, or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.
[0161] As used herein, the phrase "under transcriptional control" or "operably linked" means that the promoter is in the correct location and orientation relative to the polynucleotide to control transcription initiation by RNA polymerase and expression of the polynucleotide.
[0162] "Vector" is a composition of matter that includes an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the interior of a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ionic or amphiphilic molecular compounds, plasmids and viruses. Therefore, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be interpreted as including non-plasmid and non-viral compounds that help transfer nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc. Examples of viral vectors include but are not limited to adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, etc.
[0163] As used herein, the term "specifically binds" means an antibody or ligand that recognizes and binds to a cognate binding partner (e.g., a stimulatory and / or co-stimulatory molecule present on T cells) protein present in a sample, but the antibody or ligand does not substantially recognize or bind to other molecules in the sample.
[0164] The term "stimulation" refers to the binding of a stimulatory molecule (e.g., TCR / CD3 complex) to its associated ligand, thereby mediating a signal transduction event, such as but not limited to, via the TCR / CD3 complex. Stimulation can mediate the expression of certain molecular changes, such as downregulation of TGF-β and / or reorganization of cytoskeletal structure, etc.
[0165] As used herein, the term "stimulatory molecule" refers to a molecule on a T cell that specifically binds to a cognate stimulatory ligand present on an antigen presenting cell and / or a tumor cell.
[0166] As used herein, "stimulatory ligand" refers to a ligand that can specifically bind to a cognate binding partner (referred to herein as a "stimulatory molecule") when present on an antigen presenting cell (e.g., aAPC, dendritic cell, B cell, etc.) or tumor cell, thereby mediating a primary response of T cells, including but not limited to activation, initiation of an immune response, proliferation, etc. Stimulatory ligands are well known in the art and include, among others, MHC class I molecules loaded with peptides, anti-CD3 antibodies, superagonist anti-CD28 antibodies, and superagonist anti-CD2 antibodies.
[0167] Range: Throughout the disclosure, various aspects of the disclosure may be presented in range format. It should be understood that the description in range format is only for convenience and brevity, and should not be interpreted as a rigid limitation on the scope of the disclosure. Therefore, the description of a range should be interpreted as having specifically disclosed all possible subranges and individual values within the range. For example, a description of a range such as from 1 to 6 should be interpreted as specifically disclosing subranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within the range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
[0168] Combining peptides, antibodies and scFv
[0169] In aspects, disclosed herein are antibodies or antigen-binding fragments thereof (or "binding polypeptides," which are used interchangeably) characterized by specific functional features or properties of the antibodies or antigen-binding fragments thereof. For example, the binding polypeptides and antibodies specifically bind to canine programmed death protein 1 ("cPD-1" or "canine PD-1" are used interchangeably). The binding polypeptides and antibodies of the present disclosure can bind to canine PD-1 with high affinity. The binding polypeptides and antibodies of the present disclosure can specifically recognize canine PD-1 proteins naturally expressed on cells. In some cases, the binding polypeptides and antibodies of the present disclosure do not cross-react with other surface molecules on such cells. The binding polypeptides and antibodies of the present disclosure can specifically bind to canine PD-1 proteins naturally expressed on cells, such that such binding prevents canine PD-1 from binding to natural ligands of canine PD-1, such as canine programmed death ligand 1 ("cPD-L1" or "canine PD-L1"). In some cases, the cells are tumor cells (e.g., melanoma, non-small cell lung cancer, and hepatocellular carcinoma). In some cases, the cells are immune cells. In some cases, immune cells include T cells (e.g., activated T cells), B cells, natural killer (NK) cells, regulatory T cells, macrophages, or dendritic cells (DC). In some cases, immune cells include activated T cells. In some cases, immune cells include tumor infiltrating lymphocytes. In some cases, cPD-L1 is overexpressed on tumor cells. In some cases, antibodies or antigen-binding fragments thereof can bind to cPD-1 and inhibit the cPD-1 signaling pathway.
[0170] In certain aspects, the present disclosure provides antibodies or antigen-binding fragments thereof that specifically bind to canine programmed death protein 1 (PD-1). In some cases, the antibody or its antigen-binding fragment includes a heavy chain complementary determining region 1 (HCDR1). In some cases, the antibody or its antigen-binding fragment includes a heavy chain complementary determining region 2 (HCDR2). In some cases, the antibody or its antigen-binding fragment includes a heavy chain complementary determining region 3 (HCDR3). In some cases, the antibody or its antigen-binding fragment includes a light chain complementary determining region 1 (LCDR1). In some cases, the antibody or its antigen-binding fragment includes a light chain complementary determining region 2 (LCDR2). In some cases, the antibody or its antigen-binding fragment includes a light chain complementary determining region 3 (LCDR3). In some cases, the antibody or its antigen-binding fragment includes an antigen-binding domain that specifically binds to canine programmed death protein 1 (PD-1). In certain embodiments, the antigen-binding domain includes a heavy chain variable region including three heavy chain complementary determining regions (HCDRs) and a light chain variable region including three light chain complementary determining regions (LCDRs).
[0171] In certain aspects, the disclosure provides an isolated binding polypeptide comprising a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, 27 or 43. Also provided is an isolated binding polypeptide comprising a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, 28 or 44. Also provided is an isolated binding polypeptide comprising a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3, 29 or 45. Also provided is an isolated binding polypeptide comprising a light chain variable region comprising a LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, 30 or 46. Also provided is an isolated binding polypeptide comprising a LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, 31 or 47. Also provided is an isolated binding polypeptide comprising a LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 6, 32 or 48.
[0172] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof, comprising: a heavy chain complementary determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 1, 27 or 43, a heavy chain complementary determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO: 2, 28 or 44, a heavy chain complementary determining region 3 (HCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 3, 29 or 45, a light chain complementary determining region 1 (LCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 4, 30 or 46, a light chain complementary determining region 2 (LCDR2) comprising an amino acid sequence set forth in SEQ ID NO: 5, 31 or 47, and a light chain complementary determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 6, 32 or 48. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1). In some cases, the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33, or 49. In some cases, the antibody or antigen-binding fragment comprises a light chain variable region comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35, or 51. In some cases, the antibody or antigen-binding fragment comprises an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39, or 55. In some cases, the antibody or antigen-binding fragment comprises an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0173] In certain aspects, the disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33, or 49, and a light chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 11, 35, or 51. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0174] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 7, 9, 33, or 49 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 11, 35, or 51. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0175] In certain aspects, the disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39, or 55, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 25, 41, or 57. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0176] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39, or 55, and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41, or 57. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0177] In certain aspects, the present disclosure provides an isolated binding polypeptide comprising: a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the isolated binding polypeptide is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 7 or 9. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin light chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25.
[0178] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and a light chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 11. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0179] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0180] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0181] In certain aspects, the disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 19, 21, or 23, and an immunoglobulin light chain comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 25. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0182] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19 and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0183] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0184] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 23 and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0185] In certain aspects, the present disclosure provides an isolated binding polypeptide comprising: a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 27, a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 28, a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 29, a LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the isolated binding polypeptide is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 35. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin light chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 41.
[0186] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 33 and a light chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 35. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0187] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 33 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 35. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0188] In certain aspects, the disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39, and an immunoglobulin light chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 41. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0189] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 39 and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 41. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0190] In certain aspects, the present disclosure provides an isolated binding polypeptide comprising: a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 43, a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 44, a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 45, a LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 46, a LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48. In some embodiments, the isolated binding polypeptide is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 49. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 51. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 55. In some embodiments, the antibody or antigen-binding fragment thereof comprises an immunoglobulin light chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 57.
[0191] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence set forth in SEQ ID NO: 51. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0192] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 49 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 51. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0193] In certain aspects, the disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 55, and an immunoglobulin light chain comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 57. In some instances, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0194] In certain aspects, the present disclosure provides an antibody or antigen-binding fragment thereof comprising an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 55 and an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 57. In some cases, the antibody or antigen-binding fragment thereof specifically binds to canine programmed death protein 1 (PD-1).
[0195] The permissible variations of complementarity determining region (CDR) sequences are known to those skilled in the art. For example, in some embodiments, the isolated binding polypeptide comprises a complementarity determining region (HCDR or LCDR) comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with any one of the amino acid sequences listed in SEQ ID NO: 1, 2, 3, 4, 5, 6, 27, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47 or 48. In some embodiments, the isolated binding polypeptide comprises a complementary determining region (HCDR or LCDR) comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO: 1, 2, 3, 4, 5 or 6. In some embodiments, the isolated binding polypeptide comprises a complementary determining region (HCDR or LCDR) comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO: 27, 28, 29, 30, 31 or 32. In some embodiments, the isolated binding polypeptide comprises a complementary determining region (HCDR or LCDR) comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the amino acid sequences listed in SEQ ID NO: 43, 44, 45, 46, 47 or 48. In some embodiments, the isolated binding polypeptide is an antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (PD-1).
[0196] In some embodiments, the isolated binding polypeptide binds to programmed death protein 1 (PD-1), for example, canine PD-1. In some embodiments, the binding polypeptide comprises an antibody or an antigen-binding fragment thereof. In some embodiments, the antibody or its antigen-binding fragment is an IgG, IgM, IgE, IgA or IgD molecule. In some embodiments, the antibody or its antigen-binding fragment is derived from an IgG, IgM, IgE, IgA or IgD molecule. In some embodiments, the antigen-binding fragment is selected from a full-length antibody, Fab, a single-chain variable fragment (scFv), a single-domain antibody, sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a double antibody. In a further embodiment, the antibody is a full-length antibody. In a further embodiment, the antibody or antigen-binding fragment is a canine antibody or a caninized antibody or an antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment is a canine antibody or an antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment is a canine antibody. In some embodiments, the antibody or antigen-binding fragment is a canine IgG4 antibody. In some embodiments, the antibody or antigen binding fragment is a scFv. In some embodiments, the antibody or antigen binding fragment is a canine or caninized scFv. In some embodiments, the antibody or antigen binding fragment is a canine scFv. In some embodiments, the specific binding of the antibody or its antigen binding fragment to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1). In some embodiments, the specific binding of the antibody or its antigen binding fragment to cPD-1 inhibits the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1). In some embodiments, the specific binding of the antibody or its antigen binding fragment to cPD-1 inhibits the signal transduction pathway activated by the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1). In some embodiments, the specific binding of the antibody or its antigen binding fragment to cPD-1 inhibits the cPD-1 signaling pathway.
[0197] In certain embodiments, the binding polypeptide comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence of a heavy chain variable region set forth in SEQ ID NO: 7, 9, 33, or 49. In certain embodiments, the binding polypeptide comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33, or 49. In certain embodiments, the binding polypeptide comprises a heavy chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 7, 9, 33, or 49.
[0198] In certain embodiments, the binding polypeptide comprises a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35, or 51. In certain embodiments, the binding polypeptide comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35, or 51. In certain embodiments, the binding polypeptide comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35, or 51.
[0199] Also provided is an isolated binding polypeptide comprising: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7 or 9 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:11.
[0200] Also provided is an isolated binding polypeptide comprising: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:33 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:35.
[0201] Also provided is an isolated binding polypeptide comprising: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:49 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:51.
[0202] In certain embodiments, the present disclosure includes antibodies that bind to the same epitope on canine PD-1 as the antibodies of the present disclosure (i.e., antibodies that have the ability to cross-compete with any of the antibodies of the present disclosure for binding to canine PD-1). In a preferred embodiment, the reference antibody for cross-competition studies can be one of the antibodies described herein (e.g., P3C6mut3.1, P3C6mut3.2, P4B1, or A6 in Table 1 and Example 1). For example, Biacore analysis, ELISA assay, or flow cytometry can be used to demonstrate cross-competition with the antibodies of the present disclosure. The ability of the test antibody to inhibit, for example, the binding of P3C6mut3.1 or P3C6mut3.2 to cPD-1 indicates that the test antibody can compete with P3C6mut3.1 or P3C6mut3.2 for binding to cPD-1, and is therefore considered to bind to the same epitope of PD-1 as P3C6mut3.1 or P3C6mut3.2.
[0203] Antibodies of the present disclosure can be prepared using antibodies having one or more VH and / or VL sequences disclosed herein, or any fragments thereof, as starting materials to engineer modified antibodies that may have altered properties compared to the starting antibody. Antibodies can be engineered by modifying one or more amino acids in one or both variable regions (i.e., VH and / or VL), such as within one or more CDR regions and / or within one or more framework regions. In addition or alternatively, antibodies can also be engineered by modifying residues within the constant region(s), such as to alter the effector function(s) of the antibody.
[0204] Also provided is a canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1). The canine antibody or antigen-binding fragment thereof can be produced by a canine antibody phage display library. A method for producing a canine antibody or antigen-binding fragment thereof that specifically binds to cPD-1 is illustrated in Example 1. In some cases, such a canine antibody comprises any antigen-binding fragment or binding peptide disclosed herein. In some cases, the specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0205] Also provided is a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (PD-1). In some cases, the scFv includes an antigen binding domain. In some cases, specific binding of the antibody or antigen binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0206] As used herein, the term "single-chain variable fragment" or "scFv" is a fusion protein in which the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin (e.g., mouse, dog or human) are covalently linked to form a VH:VL heterodimer. The variable heavy chain (VH) and light chain (VL) are directly linked or linked by a linker encoding a peptide that connects the N-terminus of VH and the C-terminus of VL, or the C-terminus of VH and the N-terminus of VL. In some embodiments, the antigen binding domain (e.g., PD-1 binding domain) includes a scFv with a configuration of VH-linker-VL from the N-terminus to the C-terminus. In certain embodiments, the antigen binding domain includes a scFv with a configuration of VL-linker-VH from the N-terminus to the C-terminus. Those skilled in the art will be able to select an appropriate configuration for use in the present disclosure.
[0207] The linker is usually rich in glycine to improve flexibility, and serine or threonine to improve solubility. The linker can connect the heavy chain variable region and the light chain variable region of the extracellular antigen binding domain. Non-limiting examples of linkers are disclosed in Shen et al., Anal. Chem. 80 (6): 1910-1917 (2008) and WO 2014 / 087010, the contents of which are incorporated by reference in their entirety. Various linker sequences are known in the art, including but not limited to glycine serine (GS) linkers, such as (GS) n 、(GSGGS) n (SEQ ID NO: 65), (GGGS) n (SEQ ID NO: 66) and (GGGGS) n (SEQ ID NO: 67), wherein n represents an integer of at least 1. Exemplary linker sequences may include amino acid sequences including, but not limited to, GGSG (SEQ ID NO: 68), GGSGG (SEQ ID NO: 69), GSGSG (SEQ ID NO: 70), GSGGG (SEQ ID NO: 71), GGGSG (SEQ ID NO: 72), GSSSG (SEQ ID NO: 73), GGGGS (SEQ ID NO: 74), GGGGSGGGGSGGGGS (SEQ ID NO: 75), GGGSSRSSSSGGGGSGGGG (SEQ ID NO: 76), etc. Those skilled in the art will be able to select appropriate linker sequences for use in the present disclosure. In one embodiment, the scFv of the present disclosure comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL are connected by a linker sequence having an amino acid sequence of GGGSSRSSSSGGGGSGGGG (SEQ ID NO: 76), which can be encoded by a nucleic acid sequence of GGCGGTGGTTCCTCTAGATCTTCCTCCTCTGGTGG CGGTGGCTCGGGCGGTGGTGGG (SEQ ID NO: 77), wherein an arginine residue R is present due to the nucleotide sequence comprising restriction endonuclease Xba I. One skilled in the art will recognize that the presence of restriction enzyme sites in the linker and flanking the scFv construct facilitates heavy chain / light chain "swap" experiments to optimize antibodies when desired.
[0208] Although the constant region is removed and a linker is introduced, the scFv protein still retains the specificity of the original immunoglobulin. Single-chain Fv polypeptide antibodies can be expressed by nucleic acids including VH and VL coding sequences, as described by Huston et al. (Proc. Nat. Acad. Sci. USA, 85: 5879-5883, 1988). See also U.S. Patent Nos. 5,091,513, 5,132,405 and 4,956,778; and U.S. Patent Publication Nos. 20050196754 and 20050196754. Antagonistic scFvs with inhibitory activity have been described (e.g., see Zhao et al., Hybridoma (Larchmt) 2008 27(6):455-51; Peter et al., J Cachexia Sarcopenia Muscle, August 12, 2012; Shieh et al., J Imunol 2009 183(4):2277-85; Giomarelli et al., Thromb Haemost 2007 97(6):955-63; Fife et al., J Clin Invst 2006 116(8):2252-61; Brocks et al., Immunotechnology 1997 3(3):173-84; Moosmayer et al., Ther Immunol 1995 2(10:31-40). Antagonistic scFvs with stimulatory activity have been described (e.g., see Peter et al., J Bioi Chem 2003 25278(38):36740-7; Xie et al., Nat Biotech 1997 15(8):768-71; Ledbetter et al., Crit Rev Immunol 1997 17(5-6):427-55; Ho et al., BioChim Biophys Acta 2003 1638(3):257-66).
[0209] In certain embodiments, the antigen binding domain of the scFv comprises a heavy chain variable region comprising three heavy chain complementary determining regions (HCDRs) and a light chain variable region comprising three light chain complementary determining regions (LCDRs). HCDR1 comprises an amino acid sequence (SEQ ID NO: 1, 27 or 43), and / or HCDR2 comprises an amino acid sequence (SEQ ID NO: 2, 28 or 44), and / or HCDR3 comprises an amino acid sequence (SEQ ID NO: 3, 29 or 45), and / or LCDR1 comprises an amino acid sequence (SEQ ID NO: 4, 30 or 46), and / or LCDR2 comprises an amino acid sequence (SEQ ID NO: 5, 31 or 47), and / or LCDR3 comprises an amino acid sequence (SEQ ID NO: 6, 32 or 48). The heavy chain variable region and the light chain variable region are connected by a linker.
[0210] Also provided is a single chain variable fragment (scFv) comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51. The heavy chain variable region and the light chain variable region are connected by a linker.
[0211] In another aspect, a single chain variable fragment (scFv) comprising the amino acid sequence set forth in SEQ ID NO: 13, 15, 17, 37 or 53 is provided. In another aspect, a single chain variable fragment (scFv) consisting of the amino acid sequence set forth in SEQ ID NO: 13, 15, 17, 37 or 53 is provided.
[0212] The permissible variations of scFv sequences are known to those skilled in the art. For example, in some embodiments, the scFv comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with any of the amino acid sequences listed in SEQ ID NO: 13, 15, 17, 37 or 53.
[0213] In another aspect, a full length antibody is provided, comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57. In another aspect, a full length antibody is provided, consisting of a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0214] The permissible variations in the sequence of the full-length antibody will be known to those skilled in the art. For example, in some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the amino acid sequences listed in SEQ ID NO: 19, 21, 23, 39 or 55 and a heavy chain comprising an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the amino acid sequences listed in SEQ ID NO: A light chain of an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any of the amino acid sequences listed in NO: 25, 41 or 57.
[0215] In certain embodiments, the full-length heavy chain or light chain of the antibody or antigen-binding fragment thereof of the present disclosure further comprises a leader sequence. In certain embodiments, the leader sequence comprises the amino acid sequence listed in SEQ ID NO: 60. In certain embodiments, the leader sequence is encoded by the nucleotide sequence listed in SEQ ID NO: 59.
[0216] In certain embodiments, the full-length heavy chain of the antibody or antigen-binding fragment thereof of the present disclosure further comprises a linker and an HA or hemagglutinin tag at the carboxyl terminus of the polypeptide. In certain embodiments, the heavy chain linker and the HA tag comprise the amino acid sequence set forth in SEQ ID NO: 62. In certain embodiments, the heavy chain linker and the HA tag are encoded by the nucleotide sequence set forth in SEQ ID NO: 61.
[0217] In certain embodiments, the scFv of the present disclosure further comprises an IgG fragment and a 6xHIS or histidine-hemagglutinin tag at the carboxyl terminus of the polypeptide. In certain embodiments, the scFv IgG fragment-6x HIS-hemagglutinin tag comprises an amino acid sequence as set forth in SEQ ID NO: 64. In certain embodiments, the scFv IgG fragment-6x HIS-hemagglutinin tag is encoded by a nucleic acid sequence as set forth in SEQ ID NO: 63.
[0218] Table 1: Sequences used in this disclosure
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232] PD-1 blockade
[0233] In some aspects, the binding polypeptides, antibodies, or antigen-binding fragments thereof described in the present disclosure may bind to canine PD-1, and thus may block the interaction of canine PD-1 with its natural ligand and any downstream signaling pathways associated with such interaction. In some cases, the antibodies or antigen-binding fragments described herein may bind to the same region on canine PD-1 as the region recognized by the natural ligand of canine PD-1. In some cases, the antibodies or antigen-binding fragments described herein may bind to a region on canine PD-1 that is different from the region recognized by the natural ligand of canine PD-1. In some cases, the binding of the antibodies or antigen-binding fragments described herein to canine PD-1 will hinder the region recognized by the natural ligand of canine PD-1. In some cases, the binding of the antibodies or antigen-binding fragments described herein to canine PD-1 may prevent the interaction of canine PD-1 with its natural ligand (e.g., canine PD-L1). In some cases, the binding of the antibodies or antigen-binding fragments described herein to canine PD-1 may inhibit the canine PD-1 signaling pathway that can be activated by the natural ligand of canine PD-1 (such as PD-L1).
[0234] Programmed death protein 1 (PD-1 or PD1), also known as "programmed cell death protein 1" and CD279, is a member of the immunoglobulin superfamily of transmembrane receptors, including stimulatory receptors and regulatory receptors. The intracellular domain of PD-1 includes two phosphorylation sites located in the immunoreceptor tyrosine-based inhibitory motif (ITIM), which transmits signals that prevent T cell activation via the T cell receptor (TCR). Although PD-1 is initially It is not expressed on resting CD4+ and CD8+ T cells, but is strongly upregulated on the surface of activated T cells. The ligands of PD-1 are PD-L1 and PD-L2, which are part of the B7 receptor family and can transmit negative signals to T cells. The expression of the two PD-1 ligands can be constitutive or can be induced in a variety of cell types. PD-L1 usually responds to signals such as lipopolysaccharide (LPS), IFNγ and GM-CSF on antigen-presenting cells such as macrophages and dendritic cells, but can also be found in peripheral non-lymphocytes including microvascular endothelial cells and organ tissues such as heart and lungs. Specifically, IFNγ signaling leads to PD-L1 expression, where it helps to limit inflammation. PD-L2 is mainly expressed by antigen-presenting cells, but can also be found in a variety of tissues including the gastrointestinal tract, skeletal muscle and pancreas.
[0235] Both PD-L1 and PD-L2 are strongly expressed by many cancers as a mechanism to evade immune recognition and killing, effectively attenuating T cell responses against them. In fact, high expression of PD-1 ligands is often associated with a poor prognosis and more aggressive disease. Similarly, IFNγ signaling in the tumor microenvironment, such as that produced by the presence of anti-tumor cytotoxic CD8+ T cells, can stimulate multiple types of tumor cells to express PD-L1. Tumor-associated expression of PD-1 on tumor-infiltrating T cells and PD-L1 on tumor cells has been found in many primary cancers, including but not limited to cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer (including melanoma and squamous cell carcinoma), colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, gastric cancer, pancreatic cancer, head and neck cancer, etc.
[0236] Blockade and inhibition of the PD-1 signaling pathway are used as a therapeutic strategy for chronic infections, where inhibition of PD-1 can reverse or prevent T cell exhaustion and maintain cytotoxic function. Chronic infections include viral infections. Such infections are often characterized by exhaustion or impaired function of CD8+ T cells, which results in the inability of the subject to resolve the infection. Blocking PD-1 in animal models of chronic infection (e.g., canines or pet dogs) can prevent T cell exhaustion, maintain the number and function of responsive T cells, and improve pathogen clearance and subject survival.
[0237] The fully canine anti-PD-1 disclosed herein can be used to inhibit the PD-1 signaling pathway and thus serve as an important comparative tool for anti-tumor therapy in dogs and translational research in human immuno-oncology.
[0238] Nucleic Acids and Expression Vectors
[0239] The present disclosure provides an isolated nucleic acid encoding a polypeptide. The nucleic acid of the present disclosure may include a polynucleotide sequence encoding any of the binding polypeptides, scFvs, antibodies, or any fragments thereof disclosed herein.
[0240] One aspect of the present disclosure includes an isolated nucleic acid encoding a binding polypeptide comprising an antigen binding domain that specifically binds to canine programmed death protein 1 (PD-1).
[0241] In certain embodiments, the nucleic acid comprises an antigen binding domain comprising a heavy chain variable region comprising three heavy chain complementarity determining regions (HCDRs) and a light chain variable region comprising three light chain complementarity determining regions (LCDRs). HCDR1 comprises the amino acid sequence (SEQ ID NO: 1, 27 or 43), and / or HCDR2 comprises the amino acid sequence (SEQ ID NO: 2, 28 or 44), and / or HCDR3 comprises the amino acid sequence (SEQ ID NO: 3, 29 or 45), and / or LCDR1 comprises the amino acid sequence (SEQ ID NO: 4, 30 or 46), and / or LCDR2 comprises the amino acid sequence (SEQ ID NO: 5, 31 or 47), and / or LCDR3 comprises the amino acid sequence (SEQ ID NO: 6, 32 or 48).
[0242] In certain embodiments, the binding polypeptide comprises an antibody or an antigen-binding fragment thereof. In certain embodiments, the antigen-binding fragment is selected from Fab, a single-chain variable fragment (scFv), a single domain antibody, sc(Fv)2, dsFv, Fab, Fab', (Fab')2, and a diabody. In certain embodiments, the antibody is a full-length antibody. In certain embodiments, the antibody or antigen-binding fragment is a canine antibody or a caninized antibody or a fragment thereof.
[0243] In certain embodiments, the heavy chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 8, 10, 34 or 50.
[0244] In certain embodiments, the heavy chain variable region is encoded by a nucleic acid comprising the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50.
[0245] In certain embodiments, the heavy chain variable region is encoded by a nucleic acid consisting of the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50.
[0246] In certain embodiments, the light chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence of the light chain variable region set forth in SEQ ID NO: 12, 36 or 52. In certain embodiments, the light chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52. In certain embodiments, the light chain variable region is encoded by a nucleic acid consisting of a polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52.
[0247] Also provided is an isolated nucleic acid encoding a binding polypeptide comprising a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 8 or 10 and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 12.
[0248] Also provided is an isolated nucleic acid encoding a binding polypeptide comprising a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:34 and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:36.
[0249] Also provided is an isolated nucleic acid encoding a binding polypeptide comprising a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:50 and a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:52.
[0250] Also provided is an isolated nucleic acid encoding a single chain variable fragment (scFv), the single chain variable fragment comprising a heavy chain variable region comprising three heavy chain complementary determining regions (HCDRs) and a light chain variable region comprising three light chain complementary determining regions (LCDRs). HCDR1 comprises an amino acid sequence (SEQ ID NOs: 1, 27, and 43), and / or HCDR2 comprises an amino acid sequence (SEQ ID NOs: 2, 28, or 44), and / or HCDR3 comprises an amino acid sequence (SEQ ID NOs: 3, 29, and 45), and / or LCDR1 comprises an amino acid sequence (SEQ ID NOs: 4, 30, or 46, and / or LCDR2 comprises an amino acid sequence (SEQ ID NOs: 5, 31, or 47), and / or LCDR3 comprises an amino acid sequence (SEQ ID NOs: 6, 32, or 48).
[0251] Also provided is an isolated nucleic acid encoding a single chain variable fragment (scFv), the single chain variable fragment comprising: a heavy chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 8 or 10; and / or a light chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 12. The heavy chain variable region and the light chain variable region are connected by a linker.
[0252] Also provided is an isolated nucleic acid encoding a single-chain variable fragment (scFv), the single-chain variable fragment comprising a polynucleotide sequence listed in SEQ ID NO: 14, 16, 18, 38 or 54. Also provided is an isolated nucleic acid encoding a single-chain variable fragment (scFv), the single-chain variable fragment consisting of a polynucleotide sequence listed in SEQ ID NO: 14, 16, 18, 38 or 54.
[0253] Also provided is an isolated nucleic acid encoding a full-length antibody, the full-length antibody comprising a heavy chain polynucleotide sequence set forth in SEQ ID NO: 20, 22, 40 or 56 and a light chain polynucleotide sequence set forth in SEQ ID NO: 26, 42 or 58. Also provided is an isolated nucleic acid encoding a full-length antibody, the full-length antibody consisting of a heavy chain polynucleotide sequence set forth in SEQ ID NO: 20, 22, 40 or 56 and a light chain polynucleotide sequence set forth in SEQ ID NO: 26, 42 or 58.
[0254] Permissible variations in nucleic acid sequences will be known to those skilled in the art. For example, in some embodiments, the nucleic acid encoding the full-length heavy chain comprises a nucleotide sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the nucleotide sequences listed in SEQ ID NO: 20, 22, 40 or 56, and the nucleic acid encoding the full-length light chain comprises a nucleotide sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of the nucleotide sequences listed in SEQ ID NO: 20, 22, 40 or 56. Any of the nucleotide sequences listed in NO: 26, 42 or 58 has a nucleotide sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.
[0255] In certain embodiments, the nucleic acid of the present disclosure includes a first polynucleotide sequence and a second polynucleotide sequence. The first and second polynucleotide sequences can be connected by a joint. For example, in certain embodiments, the heavy chain variable region and the light chain variable region of the scFv are connected by a joint. In certain embodiments, the nucleic acid includes a first polynucleotide sequence, a joint and a second polynucleotide sequence from 5' to 3'. In certain embodiments, the nucleic acid includes a second polynucleotide sequence, a joint and a first polynucleotide sequence from 5' to 3'.
[0256] Another aspect of the present disclosure provides a vector comprising any of the isolated nucleic acids disclosed herein. In certain embodiments, the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, and a retroviral vector. In certain embodiments, the vector is an expression vector.
[0257] A host cell comprising any vector or nucleic acid disclosed herein is also provided. The host cell may be of eukaryotic, prokaryotic, mammalian or bacterial origin. Non-limiting examples of cells that can be used to express the antigen-binding fragments of anti-PD-1 antibodies or scFv disclosed herein include human embryonic kidney (HEK) cell lines (e.g., HEK293), Chinese hamster ovary (CHO) cell lines, miniature hamster kidney (BHK) cell lines, COS cell lines, Martin Darby canine kidney (MDCK) cell lines, and HeLa cell lines. In some cases, the host cell is a Chinese hamster ovary cell.
[0258] Also provided herein is a method for producing an antibody, binding polypeptide or scFv that binds to canine PD-1, wherein the method comprises culturing a host cell. In some embodiments, the method further comprises culturing the host cell in a cell culture medium under conditions sufficient to express and secrete the anti-PD-1 antibody or antigen-binding fragment thereof or scFv described herein.
[0259] In some embodiments, the nucleic acids of the present disclosure may be operably linked to transcriptional control elements, such as promoters and enhancers, etc. Suitable promoter and enhancer elements are known to those skilled in the art.
[0260] In certain embodiments, the nucleic acid is operably linked to a promoter. In certain embodiments, the promoter is a phosphoglycerate kinase-1 (PGK) promoter.
[0261] For expression in bacterial cells, suitable promoters include, but are not limited to, lacI, lacZ, T3, T7, gpt, lambda P, and trc. For expression in eukaryotic cells, suitable promoters include, but are not limited to, light chain and / or heavy chain immunoglobulin gene promoters and enhancer elements; cytomegalovirus early promoter; herpes simplex virus thymidine kinase promoter; early and late SV40 promoters; promoters present in retroviral long terminal repeats; mouse metallothionein-I promoter; and various tissue-specific promoters known in the art. Suitable reversible promoters, including reversible inducible promoters, are known in the art. Such reversible promoters can be isolated and extracted from many organisms, for example, eukaryotes and prokaryotes. It is well known in the art to modify a reversible promoter derived from a first organism for use in a second organism, for example, a first prokaryote and a second eukaryote, a first eukaryote and a second prokaryote, etc. Such reversible promoters and systems based on such reversible promoters but also including additional control proteins include, but are not limited to, alcohol-regulated promoters (e.g., alcohol dehydrogenase I (alcA) gene promoters, promoters responsive to alcohol conversion activator protein (A1cR), etc.), tetracycline-regulated promoters (e.g., promoter systems including TetActivators, TetON, TetOFF, etc.), steroid-regulated promoters (e.g., rat glucocorticoid receptor promoter system, human estrogen receptor promoter system, retinoid promoter system, thyroid promoter system, ecdysone promoter system, mifepristone promoter system, etc.), metal-regulated promoters (e.g., metallothionein promoter system, etc.), pathogenesis-related regulated promoters (e.g., salicylic acid regulated promoters, ethylene regulated promoters, benzothiadiazole regulated promoters, etc.), temperature-regulated promoters (e.g., heat shock-inducible promoters (e.g., HSP-70, HSP-90, soybean heat shock promoter, etc.), light-regulated promoters, synthetic inducible promoters, etc.
[0262] For expression in yeast cells, suitable promoters are constitutive promoters, such as ADH1 promoter, PGK1 promoter, ENO promoter, PYK1 promoter, etc.; or regulatable promoters such as GAL1 promoter, GAL10 promoter, ADH2 promoter, PHOS promoter, CUP1 promoter, GALT promoter, MET25 promoter, MET3 promoter, CYC1 promoter, HIS3 promoter, ADH1 promoter, PGK promoter, GAPDH promoter, ADC1 promoter, TRP1 promoter, URA3 promoter, LEU2 promoter, ENO promoter, TP1 promoter and AOX1 (e.g., for Pichia). Selecting suitable vectors and promoters is well within the level of those skilled in the art.Suitable promoters for prokaryotic host cells include, but are not limited to, bacteriophage T7 RNA polymerase promoter; trp promoter; lac operator promoter; mixed promoters, such as lac / tac mixed promoter, lac / tac mixed promoter, tac / trc mixed promoter, trp / lac promoter, T7 / lac promoter; trc promoter; tac promoter, etc.; araBAD promoter; in vivo regulated promoters, such as ssaG promoter or related promoters (see, e.g., U.S. Patent Publication No. 20040131637), pagC promoter (Pulkkinen and Miller, J. Bacteriol. (1991) 173(1): 86-93; Alpuche-Aranda et al., Proc. Natl. USA (1992) 89(21): 10079-83), nirB promoter (Harborne et al., Mol. Micro. (1992) 6: 2805-2813), etc. (see, e.g., Dunstan et al., Infect. Immun. (1999) 67: 5133-5141; McKelvie et al., Vaccine (2004) 22: 3243-3255; and Chatfield et al., Biotechnol. (1992) 10: 888-892); σ70 promoter promoters, e.g., the consensus σ70 promoter (see, e.g., GenBank Accession Nos. AX798980, AX798961, and AX798183); stationary phase promoters, e.g., dps promoter, spv promoter, etc.; promoters derived from pathogenicity island SPI-2 (see, e.g., WO 96 / 17951); actA promoter (see, e.g., Shetron-Rama et al., Infect. Immun. (2002) 70:1087-1096); rpsM promoter (see, e.g., Valdivia and Falkow et al., Infect. Immun. (2002) 70:1087-1096); Mol.Microbiol.(1996).22:367); tet promoter (see, e.g., Hillen, W. and Wissmann, A. (1989) In Saenger, W. and Heinemann, U. (eds.), Topics in Molecular and Structural Biology, Protein--Nucleic Acid Interaction. Macmillan, London, UK, Vol. 10, pp. 143-162); SP6 promoter (see, e.g., Melton et al., Nucl. Acids Res. (1984) 12:7035); etc.Suitable strong promoters for prokaryotes (e.g., E. coli) include, but are not limited to, Trc, Tac, T5, T7, and PLambda. Non-limiting examples of operators for bacterial host cells include the lactose-promoted operator (the LacI repressor changes conformation when in contact with lactose, thereby preventing the Lad repressor from binding to the operator), the tryptophan-promoted operator (when complexed with tryptophan, the TrpR repressor has a conformation in which it binds to the operator; in the absence of tryptophan, the TrpR repressor has a conformation in which it does not bind to the operator), and the tac-promoted operator (see, e.g., deBoer et al., Proc. Natl. Acad. Sci. USA (1983) 80: 21-25).
[0263] Other examples of suitable promoters include the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive high-level expression of any polynucleotide sequence operably linked thereto. Other constitutive promoter sequences may also be used, including but not limited to the Simian Virus 40 (SV40) early promoter, the mouse mammary tumor virus (MMTV) or the human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, the MoMuLV promoter, the avian leukosis virus promoter, the Epstein-Barr virus (Epstein-Barr virus) early promoter, the Rous sarcoma (Rous sarcom) virus promoter, the EF-1α promoter, and human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. In addition, the present disclosure should not be limited to the use of constitutive promoters. It is also contemplated that inducible promoters may be used as part of the present disclosure. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence to which it is operably linked when such expression is desired, or turn off expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0264] In some embodiments, a locus or construct or transgene containing a suitable promoter is irreversibly converted by induction of an induction system. Suitable systems for inducing irreversible conversion are well known in the art, for example, induction of irreversible conversion can utilize Cre-lox mediated recombination (see, for example, Fuhrmann-Benzakein et al., Proc. Natl. Sci. USA (2000) 28: e99, the disclosure of which is incorporated herein by reference). Any suitable combination of recombinases, endonucleases, ligases, recombination sites, etc. known in the art can be used to generate irreversible conversion promoters. The methods, mechanisms, and requirements for performing site-specific recombination described elsewhere herein can be used to generate irreversible conversion promoters and are well known in the art, see, for example, Grindley et al., Annual Review of Biochemistry (2006) 567-605; and Tropp, Molecular Biology (2012) (Jones & Bartlett Publishers, Sudbury, Mass.), the disclosure of which is incorporated herein by reference.
[0265] The nucleic acids of the present disclosure may be present in expression vectors and / or cloning vectors. The expression vectors may include selection markers, replication origins, and other features that provide replication and / or maintenance of the vector. Suitable expression vectors include, for example, plasmids, viral vectors, and the like. A large number of suitable vectors and promoters are known to those skilled in the art; many are commercially available for the production of recombinant constructs. The following vectors are provided by way of example and should not be construed as limiting in any way: Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA); pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala, Sweden). Eukaryotic: pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene) pSVK3, pBPV, pMSG and pSVL (Pharmacia).
[0266] The expression vector usually has convenient restriction enzyme sites near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous proteins. Operable selection markers may be present in the expression host. Suitable expression vectors include, but are not limited to, viral vectors (e.g., vaccinia virus-based viral vectors; poliovirus; adenovirus (see, e.g., Li et al., Invest. Opthalmol. Vis. Sci. (1994) 35:2543-2549; Borras et al., Gene Ther. (1999) 6:515-524; Li and Davidson, Proc. Natl. Acad. Sci. USA (1995) 92:7700-7704; Sakamoto et al., H. Gene Ther. (1999) 5:1088-1097; WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655); adeno-associated virus (see, e.g., Ali et al., Hum. Gene Ther. (1998) 9: 81-86, Flannery et al., Proc. Natl. Acad. Sci. USA (1997) 94: 6916-6921; Bennett et al., Invest. Opthalmol. Vis. Sci. (1997) 38: 2857-2863; Jomary et al., Gene Ther. (1997) 4: 683690, Rolling et al., Hum. Gene Ther. (1999) 10: 641-648; Ali et al., Hum. Mol. Genet. (1996) 5: 591-594; WO 93 / 09239, Srivastava in Samulski et al., J. Vir. (1989) 63:3822-3828; Mendelson et al., Virol. (1988) 166:154-165; and Flotte et al., Proc. Natl. Acad. Sci. USA (1993) 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Mi Yoshi et al., Proc. Natl. Acad. Sci. USA (1997) 94: 10319-23; Takahashi et al., J. Virol. (1999) 73: 7812-7816); retroviral vectors (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses, such as Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); etc.
[0267] Other expression vectors suitable for use are, for example, but not limited to, lentiviral vectors, gamma retroviral vectors, foamy virus vectors, adeno-associated virus vectors, adenoviral vectors, poxvirus vectors, herpesvirus vectors, engineered hybrid virus vectors, transposon-mediated vectors, etc. Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, Molecular Cloning: A Laboratory Manual, Vol. 1-4, Cold Spring Harbor Press, NY) and other virology and molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses.
[0268] In general, suitable vectors contain an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (eg, WO 01 / 96584; WO 01 / 29058; and US Pat. No. 6,326,193).
[0269] In some embodiments, an expression vector (e.g., a lentiviral vector) can be used to introduce nucleic acid into a host cell. Therefore, the expression vector (e.g., a lentiviral vector) of the present disclosure may include a nucleic acid encoding a polypeptide. In some embodiments, the expression vector (e.g., a lentiviral vector) will include additional elements that contribute to the functional expression of the polypeptide encoded therein. In some embodiments, the expression vector comprising a nucleic acid encoding a polypeptide further includes a mammalian promoter. In one embodiment, the vector further includes an elongation factor-1-α promoter (EF-1α promoter). The use of the EF-1α promoter can improve the expression efficiency of downstream transgenes. Physiological promoters (e.g., EF-1α promoters) are unlikely to induce integration-mediated genotoxicity and may weaken the ability of retroviral vectors to transform stem cells. Other physiological promoters suitable for use in vectors (e.g., lentiviral vectors) are known to those skilled in the art and can be incorporated into the vectors of the present disclosure. In some embodiments, the vector (e.g., a lentiviral vector) further includes a non-essential cis-acting sequence that can increase titer and gene expression. A non-limiting example of a non-essential cis-acting sequence is a central polypurine tract and central termination sequence (cPPT / CTS), which is very important for efficient reverse transcription and nuclear import. Other non-essential cis-acting sequences are known to those skilled in the art and can be incorporated into the vector (e.g., lentiviral vector) of the present disclosure. In some embodiments, the vector further includes a post-transcriptional regulatory element. The post-transcriptional regulatory element can improve RNA translation, improve transgenic expression, and stabilize RNA transcripts. An example of a post-transcriptional regulatory element is a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). Therefore, in some embodiments, the vector of the present disclosure further includes a WPRE sequence. Various post-transcriptional regulatory elements are known to those skilled in the art and can be incorporated into the vector (e.g., lentiviral vector) of the present disclosure. The vector of the present disclosure may further include additional elements, such as a rev response element (RRE), a packaging sequence, and 5' and 3' long terminal repeats (LTR) for RNA transport. The term "long terminal repeat" or "LTR" refers to a base pair domain located at the end of retroviral DNA, which includes the U3, R and U5 regions. LTRs generally provide functions required for retroviral gene expression (e.g., promotion, initiation and polyadenylation of gene transcripts) and viral replication. In one embodiment, a vector (e.g., a lentiviral vector) of the present disclosure includes a 3'U3 deleted LTR. Therefore, a vector (e.g., a lentiviral vector) of the present disclosure includes any combination of elements described herein to improve the efficiency of transgenic functional expression.For example, in addition to the nucleic acid encoding CAR, the vector of the present disclosure (eg, a lentiviral vector) may include a WPRE sequence, a cPPT sequence, an RRE sequence, a 5' LTR, and a 3' U3 deleted LTR'.
[0270] The vector of the present disclosure can be a self-inactivating vector. As used herein, the term "self-inactivating vector" refers to a vector in which the 3'LTR enhancer promoter region (U3 region) has been modified (e.g., by deletion or replacement). The self-inactivating vector prevents viral transcription from exceeding the first round of viral replication. Therefore, the self-inactivating vector can only infect the host genome (e.g., mammalian genome) once, and then integrate into it, and cannot continue to be transmitted. Therefore, the self-inactivating vector can greatly reduce the risk of producing replication-competent viruses.
[0271] In some embodiments, the nucleic acid of the present disclosure can be RNA, for example, RNA synthesized in vitro. Methods for synthesizing RNA in vitro are known to those skilled in the art; any known method can be used to synthesize RNA comprising a sequence encoding a polypeptide of the present disclosure. Methods for introducing RNA into host cells are known in the art. For example, see Zhao et al., Cancer Res. (2010) 15: 9053. The introduction of RNA comprising a nucleotide sequence encoding a polypeptide of the present disclosure into a host cell can be performed in vitro, ex vivo, or in vivo. For example, host cells (e.g., NK cells, cytotoxic T lymphocytes, etc.) can be electroporated in vitro or ex vivo with RNA comprising a nucleotide sequence encoding a polypeptide of the present disclosure.
[0272] In order to evaluate the expression of the polypeptide or its part, the expression vector to be introduced into the cell may also contain a selectable marker gene or a reporter gene, or both, so as to identify and select expressing cells from a cell population that is attempted to be transfected or infected by a viral vector. In some embodiments, the selectable marker may be carried on a separate DNA fragment and used in a co-transfection process. Both the selectable marker and the reporter gene may be flanked by appropriate regulatory sequences to achieve expression in the host cell. Useful selectable markers include, but are not limited to, antibiotic resistance genes.
[0273] Reporter genes can be used to identify potential transfected cells and evaluate the function of regulatory sequences. In general, reporter genes are genes that are not present or expressed in the recipient organism or tissue and encode a polypeptide, and their expression is manifested as a certain easily detectable property, such as enzyme activity. The expression of the reporter gene is evaluated at an appropriate time after the DNA is introduced into the recipient cell. Suitable reporter genes may include, but are not limited to, genes encoding luciferase, β-galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase or green fluorescent protein genes (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82).
[0274] In some embodiments, nucleic acids of the disclosure are provided for use in producing polypeptides described herein, for example, in a host cell. In some embodiments, nucleic acids of the disclosure provide for amplification of nucleic acids encoding polypeptides.
[0275] Immunoconjugates
[0276] The present disclosure also provides an immunoconjugate comprising any of the anti-PD-1 antibodies or antigen-binding fragments or scFvs disclosed herein. In some embodiments, the immunoconjugate comprises a disclosed antibody or antigen-binding fragment or scFv linked to an agent. In some embodiments, the immunoconjugate comprises a bispecific molecule disclosed herein linked to an agent. The agent may be a therapeutic agent. The agent may be a diagnostic agent.
[0277] For diagnostic agents, suitable reagents may include detectable labels. Non-limiting examples of detectable labels include radioisotopes for whole body imaging, as well as radioisotopes, enzymes, fluorescent labels, and other suitable antibody labels for sample testing. The detectable label that may be attached to any anti-PD-1 antibody described herein may be any of the various types currently used in the field of in vitro diagnostics, including particulate labels, including metal sols (such as colloidal gold); isotopes, such as I present with, for example, N2S2, N3S or N4 type peptide chelators; 125 or 99m Tc; chromophores, including fluorescent labels, luminescent labels, phosphorescent labels, etc.; and enzyme labels that convert a given substrate into a detectable label; and polynucleotide labels that are visualized after amplification (such as by polymerase chain reaction). Suitable enzyme labels include horseradish peroxidase, alkaline phosphatase, etc. For example, the label can be measured in 1,2-dioxetane substrates (such as adamantyl methoxyphosphoryloxyphenyldioxetane (AMPPD), 3-(4-(methoxyspiro{l,2-dioxetane-3,2'-(5'-chloro)tricyclo{3.3.1.1 3,7}decane}-4-yl)phenyl phosphate disodium (CSPD) and CDP and ) or other luminescent substrates well known to those skilled in the art (e.g., chelates of suitable lanthanides such as terbium (III) and europium (III)). The detection means is determined by the selected label. The appearance of the label or its reaction product can be obtained using the naked eye (in the case where the label is particulate and aggregated at an appropriate level) or using instruments such as spectrophotometers, luminometers, fluorometers, all in accordance with standard practice.
[0278] In some embodiments, the conjugation method produces substantially (or nearly) non-immunogenic bonds, such as peptide bonds (i.e., amide bonds), sulfide bonds (steric hindrance), disulfide bonds, hydrazone bonds, and ether bonds. These bonds are nearly non-immunogenic and show reasonable stability in serum; see, e.g., Senter, PD, Curr. Opin. Chem. Biol. 13 (2009) 235-244; WO 2009 / 059278; WO 95 / 17886.
[0279] Different conjugation strategies can be used, depending on the biochemical properties of the reagent and the anti-PD-1 antibody or scFv. In the case where the reagent is a naturally occurring or recombinant amino acid between 50 and 500, there are standard procedures for describing the synthesis chemistry of protein conjugates in textbooks, and technicians can easily follow these procedures (see, for example, Hackenberger, CPR and Schwarzer, D., Angew. Chem. Int. Ed. 47 (2008) 10030-10074). In some embodiments, a maleimide reagent is used to react with a cysteine residue in an antibody or reagent. In the case of using, for example, an antibody Fab or Fab'-fragment, this is a particularly suitable coupling chemical reaction. Alternatively, in some embodiments, coupling is performed with the C-terminus of an antibody or reagent. Proteins, such as C-terminal modifications of Fab fragments, can be performed as described (Sunbul, M. and Yin, J., Org. Biomol. Chem. 7 (2009) 3361-3371).
[0280] In general, site-specific reactions and covalent couplings are based on converting natural amino acids into amino acids with reactivity orthogonal to the reactivity of other functional groups present. For example, specific cysteines in rare sequence contexts can be enzymatically converted in aldehydes (see Frese, MA and Dierks, T., ChemBioChem.10 (2009) 425-427). It is also possible to obtain desired amino acid modifications by utilizing the specific enzymatic reactivity of certain enzymes with natural amino acids in a given sequence context (see, e.g., Taki, M. et al., Prot. Eng. Des. Sel.17 (2004) 119-126; Gautier, A. et al., Chem. Biol.15 (2008) 128-136; and Bordusa, F. Protease-catalyzed formation of C-Nbonds is used, Highlights in Bioorganic Chemistry (2004) 389-403). Site-specific reactions and covalent couplings can also be achieved through the selective reaction of the terminal amino acid with appropriate modifying agents.
[0281] The reactivity of the N-terminal cysteine with benzonitrile (see Ren, H. et al., Angew. Chem. Int. Ed. Engl. 48 (2009) 9658-9662) can be used to achieve site-specific covalent coupling.
[0282] Native chemical ligation can also rely on a C-terminal cysteine residue (Taylor, E. Vogel; Imperiali, B, Nucleic Acids and Molecular Biology (2009), 22 (Protein Engineering), 65-96). US6437095 B1 describes a conjugation method based on the faster reaction of a cysteine in a negatively charged amino acid fragment with a cysteine located in a positively charged amino acid fragment.
[0283] The reagent may also be a synthetic peptide or a peptide mimetic. In the case of chemically synthesized polypeptides, amino acids with orthogonal chemical reactivity may be incorporated during such synthesis (see, e.g., de Graaf, AJ et al., Bioconjug. Chem. 20 (2009) 1281-1295). Since a variety of orthogonal functional groups are at stake and can be introduced into synthetic peptides, conjugation of such peptides to linkers is standard chemistry.
[0284] To obtain singly labeled polypeptides, the 1:1 stoichiometric conjugate can be separated from other conjugation byproducts by chromatography. The use of dye-labeled binding pair members and charged linkers facilitates this process. By using such labeled, highly negatively charged binding pair members, the singly conjugated polypeptides are easily separated from unlabeled polypeptides and polypeptides carrying more than one linker, as differences in charge and molecular weight can be used for separation. Fluorescent dyes can be used to purify the complex from unbound components, just as labeled monovalent binders can be used.
[0285] In some embodiments, the agent linked to the anti-CPD-1 antibody is selected from a binding moiety, a labeling moiety, and a biologically active moiety.
[0286] The anti-CPD-1 antibodies described herein may also be conjugated to a therapeutic agent to form an immunoconjugate, such as an antibody-drug conjugate (ADC). Suitable therapeutic agents include antimetabolites, alkylating agents, DNA minor groove binders, DNA intercalators, DNA cross-linking agents, histone deacetylase inhibitors, nuclear export inhibitors, proteasome inhibitors, topoisomerase I or II inhibitors, heat shock protein inhibitors, tyrosine kinase inhibitors, antibiotics, and anti-mitotic agents. In an ADC, the antibody and therapeutic agent are preferably conjugated via a cleavable linker (such as a peptidyl, disulfide, or hydrazone linker). In some embodiments, the linker is a peptidyl linker, such as Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Pro-Val-G1y-Val-Val (SEQ ID NO: 78), Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser or G1u. ADCs can be prepared as described in U.S. Patent Nos. 7,087,600; 6,989,452; and 7,129,261; PCT Publications WO 02 / 096910; WO 07 / 038658; WO 07 / 051081; WO 07 / 059404; WO 08 / 083312; and WO 08 / 103693; U.S. Patent Publications 20060024317; 20060004081; and 20060247295.
[0287] The anti-cPD-1 antibodies or scFvs described herein can also be used to detect canine PD-1, such as cPD-1, in tissues or tissue samples. The antibodies can be used, for example, in ELISA assays or flow cytometry. In some embodiments, the anti-cPD-1 antibody is contacted with a cell (e.g., a cell in a tissue) for a time suitable for specific binding to occur, and then a reagent (e.g., an antibody for detecting the anti-cPD-1 antibody) is added. Exemplary assays are provided in the Examples. The anti-cPD-1 antibody can be a fully canine antibody. The anti-cPD-1 antibody can be a caninized antibody or a chimeric antibody. An exemplary method for detecting cPD-1 in a sample (cell or tissue sample) includes: (i) contacting the sample with an anti-cPD-1 antibody for a time sufficient for the anti-cPD-1 antibody to specifically bind to cPD-1 in the sample; (2) contacting the sample with a detection reagent (e.g., an antibody) that specifically binds to an anti-cPD-1 antibody, such as the Fc region of an anti-cPD-1 antibody, thereby detecting cPD-1 bound to the anti-cPD-1 antibody. After incubation with the antibody and / or detection reagent, a wash step may also be included. The anti-cPD-1 antibody used in these methods does not have to be linked to a label or detection reagent, as a separate detection reagent may be used.
[0288] Bispecific molecules
[0289] The anti-cPD-1 antibodies, antigen-binding fragments thereof, or scFvs described herein can be used to form bispecific molecules. The anti-cPD-1 antibodies or antigen-binding fragments thereof can be derivatized or linked to another functional molecule, such as another peptide or protein (e.g., another antibody or receptor ligand), to generate bispecific molecules that bind to at least two different binding sites or target molecules.
[0290] For example, anti-cPD-1 antibodies can be linked to antibodies or scFvs that specifically bind to any protein, which can be used as potential targets for combined therapy. In fact, the antibodies described herein can be derived or linked to more than one other functional molecule to produce multispecific molecules that bind to more than two different binding sites and / or target molecules; as used herein, the term "bispecific molecule" is also intended to include such multispecific molecules. In order to produce the bispecific molecules described herein, the antibodies described herein can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or other means) to one or more other binding molecules (e.g., another antibody, antibody fragment, peptide or binding mimetic) to produce bispecific molecules.
[0291] Provided herein are bispecific molecules comprising at least one first binding specificity for canine PD-1 and a second binding specificity for a second target epitope. In some embodiments where the bispecific molecules described herein have multispecificity, the molecule may further comprise a third binding specificity.
[0292] In some embodiments, the bispecific molecules described herein include at least one antibody or antibody fragment thereof, including, for example, Fab, Fab', F(ab')2, Fv or single-chain Fv (scFv), as a binding specificity. The antibody can also be a light chain or heavy chain dimer, or any minimal fragment thereof, such as an Fv or single-chain construct.
[0293] In some embodiments, canine monoclonal antibodies are used in the bispecific molecules. In other embodiments, other antibodies that can be used in the bispecific molecules described herein are murine antibodies, chimeric antibodies, and caninized monoclonal antibodies.
[0294] The bispecific molecules described herein can be prepared by conjugating the constituent binding specificities using methods known in the art. For example, each binding specificity of the bispecific molecule can be generated separately and then conjugated to each other. When the binding specificity is a protein or peptide, various coupling agents or cross-linking agents can be used for covalent conjugation. Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetylthioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxylate (sulfo-SMCC) (see, e.g., Karpovsky et al., (1984) J. Exp. Med. 160:1686; Fiu, MA et al., (1985) Proc. Natl. Acad. Sci. USA 82:8648). Other methods include those described in Paulus (1985) Behring Ins. Mitt. No. 78, 118-132; Brennan et al., (1985) Science 229: 81-83 and Glennie et al., (1987) J. Immunol. 139: 2367-2375. Some conjugation reagents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).
[0295] When the binding specificities are antibodies, conjugation can be accomplished via sulfhydryl bonds at the C-terminal hinge regions of the two heavy chains. In some embodiments, the hinge region is modified prior to conjugation to contain an odd number, preferably one, of sulfhydryl residues.
[0296] Alternatively, the two binding specificities can be encoded in the same vector and expressed and assembled in the same host cell. This approach is particularly useful when the bispecific molecule is a mAh x mAh, mAh x Fab, mAh x (scFv) 2, Fab x F(ab') 2 or ligand x Fab fusion protein. The bispecific antibody may include an antibody containing a scFv at the C-terminus of each heavy chain. The bispecific molecules described herein may be single chain molecules including a single chain antibody and a binding determinant, or single chain bispecific molecules including two binding determinants. The bispecific molecule may include at least two single chain molecules. Methods for making bispecific molecules are described, for example, in U.S. Pat. No. 5,260,203; U.S. Pat. No. 5,455,030; U.S. Pat. No. 4,881,175; U.S. Pat. No. 5,132,405; U.S. Pat. No. 5,091,513; U.S. Pat. No. 5,476,786; U.S. Pat. No. 5,013,653; U.S. Pat. No. 5,258,498; and U.S. Pat. No. 5,482,858.
[0297] Binding of the bispecific molecule to its specific target can be confirmed using art-recognized methods such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays typically detects the presence of a protein-antibody complex of particular interest by using a labeled reagent (e.g., antibody) specific for the complex of interest.
[0298] Treatment
[0299] In some aspects, the present disclosure provides a method of inhibiting a canine programmed death protein 1 (cPD-1) signaling pathway in a subject in need thereof, comprising administering to the subject an antibody, binding polypeptide, and scFv described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these. In some cases, the subject suffers from cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection). The composition may include a pharmaceutical composition and further include a pharmaceutically acceptable carrier. A therapeutically effective amount of the pharmaceutical composition may be administered to a subject (e.g., a dog or canine).
[0300] In some aspects, the present disclosure provides a method for increasing T cell proliferation and reducing T cell exhaustion in a subject in need, comprising administering to the subject an antibody, binding polypeptide and scFv described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these. In some cases, the subject suffers from cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection). The composition may include a pharmaceutical composition and further include a pharmaceutically acceptable carrier. A therapeutically effective amount of the pharmaceutical composition may be administered to a subject (e.g., a dog or dog). In some cases, relative to a control dog subject not given an antibody, binding polypeptide and scFv described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these, T cell proliferation in a dog subject increases by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%. In some cases, T cell exhaustion in a canine subject is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% relative to a control canine subject not administered an antibody, binding polypeptide, and scFv described herein, or a bispecific molecule, immunoconjugate, or a composition comprising any of these. In some embodiments, the T cell is an effector T cell. In some embodiments, the T cell is a CD5+ T cell.
[0301] In some aspects, the disclosure provides a method for increasing IFNγ production in a subject in need, comprising administering to the subject an antibody, binding polypeptide and scFv described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these. In some cases, the subject suffers from cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection). The composition may include a pharmaceutical composition and further include a pharmaceutically acceptable carrier. The pharmaceutical composition of a therapeutically effective amount may be administered to a subject (e.g., a dog or dog). In some cases, relative to a control dog subject not given an antibody, binding polypeptide and scFv described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these, the IFNγ production in the dog subject increases by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%. In some embodiments, T cells are CD5+T cells.
[0302] In one aspect, the disclosure provides a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject an antibody, binding polypeptide and scFv as described herein, or a bispecific molecule, an immunoconjugate, or a composition comprising any of these. The disease or condition comprises cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection). The composition may comprise a pharmaceutical composition and further comprise a pharmaceutically acceptable carrier. A therapeutically effective amount of the pharmaceutical composition may be administered to a subject (e.g., a dog or canine).
[0303] In certain embodiments, described herein are antibodies, binding polypeptides and scFvs described herein, or bispecific molecules, immunoconjugates or compositions comprising any of these for use as medicaments.
[0304] In certain embodiments, described herein are antibodies, binding polypeptides and scFvs, or bispecific molecules, immunoconjugates, or compositions comprising any of these described herein for use as medicaments for treating cancer, sepsis or septic shock, or chronic infection.
[0305] In certain embodiments, described herein is the use of an antibody, binding polypeptide and scFv, or bispecific molecule, immunoconjugate, or a composition comprising any of these described herein for the manufacture of a medicament.
[0306] In certain embodiments, described herein are uses of the antibodies, binding polypeptides, and scFvs, or bispecific molecules, immunoconjugates, or compositions comprising any of these described herein for the manufacture of a medicament for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0307] Treatment refers to a method intended to improve or alleviate the condition being treated. In the case of cancer, treatment includes, but is not limited to, reducing tumor volume, reducing the growth of tumor volume, increasing progression-free survival or overall life expectancy. In certain embodiments, treatment will affect the remission of the cancer being treated. In certain embodiments, treatment includes use as a preventive or maintenance dose intended to prevent the recurrence or worsening of a previously treated cancer or tumor. Those skilled in the art understand that not all individuals will respond equally or completely to the administered treatment, and nonetheless, such individuals are considered to have received treatment.
[0308] The method comprises administering to a subject an isolated binding polypeptide comprising a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 7, 9, 33 or 49, and a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 11, 35 or 51.
[0309] In certain embodiments, the cancer is associated with the programmed death protein 1 (PD-1) signaling pathway. In certain embodiments, PD-1 is expressed on an immune cell of the subject. In certain embodiments, the immune cell is a T lymphocyte. In certain embodiments, the immune cell is a tumor infiltrating lymphocyte. In certain embodiments, a ligand for PD-1, such as PD-L1 or PD-L2, is expressed on a cancer cell of the subject. In certain embodiments, canine programmed death ligand 1 is overexpressed on a cancer cell of the subject.
[0310] In certain embodiments, the binding polypeptide specifically binds to programmed death protein 1 (PD-1). In certain embodiments, the binding polypeptide comprises an antibody or an antigen binding fragment thereof. In certain embodiments, the antigen binding fragment is selected from Fab, a single chain variable fragment (scFv), a single domain antibody, sc(Fv)2, dsFv, Fab, Fab', (Fab')2, and a diabody. In certain embodiments, the antibody is a full-length antibody. In certain embodiments, the antibody or antigen binding fragment is a canine antibody or an antigen binding fragment thereof.
[0311] In certain embodiments, the method further includes administering one or more other therapies or interventions. This other therapy or intervention is not limited and may include any therapeutic agent or small molecule drug that helps treat a subject in need. In some embodiments, other therapy or intervention is administered as a conjoint therapy with an antibody as described herein or its antigen-binding fragment or scFv, or a bispecific molecule or an immunoconjugate including these. The non-limiting examples of other therapies or interventions include chemotherapy (e.g., asparaginase, buspircycline, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine and / or vincristine), radiotherapy, immunotherapy and other targeted therapies.
[0312] In certain embodiments, the cancer or tumor is a solid cancer or tumor. In certain embodiments, the cancer or tumor is a blood cancer or tumor. In certain embodiments, the cancer or tumor includes breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head, neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testis and liver tumors. In certain embodiments, tumors that can be treated with antibodies of the present disclosure include adenoma, adenocarcinoma, angiosarcoma, astrocytoma, epithelial cancer, germ cell tumor, glioblastoma, glioma, hemangioendothelioma, hemangiosarcoma, hematoma, hepatoblastoma, leukemia, lymphoma, medulloblastoma, melanoma, neuroblastoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, sarcoma and / or teratoma. In certain embodiments, the tumor / cancer is selected from acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous (acral lentiginous lentiginous melanoma, actinic keratosis, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenosarcoma, adenosquamous carcinoma, astrocytoma, Bartholin's gland carcinoma, basal cell carcinoma, bronchial adenocarcinoma, capillary carcinoid, carcinoma, carcinosarcoma, bile duct carcinoma, chondroma, cystadenoma, endothelial sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrial adenocarcinoma, epithelial sarcoma, swing sarcoma, focal nodular hyperplasia, gastric adenoma, germline tumor, glioblastoma, glucagonoma, hemangioblastoma, hemangioendothelioma, hemangioma, hemangioma, hepatic adenoma, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, intraepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, liposarcoma, lung cancer, lymphoma Cell leukemia, lymphocytic leukemia, leiomyosarcoma, melanoma, malignant melanoma, malignant mesothelioma, schwannoma, medulloblastoma, medulloblastoma, medullary epithelioma, mesothelioma, mucoepidermoid carcinoma, myeloid leukemia, neuroblastoma, neuroepithelial adenocarcinoma, nodular melanoma, osteosarcoma, ovarian cancer, papillary serous adenocarcinoma, pituitary tumor, plasmacytoma, pseudosarcoma, prostate cancer, pneumocystis carcinoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, squamous cell carcinoma, small cell carcinoma, soft tissue cancer, somatostatin secreting tumor, squamous carcinoma, squamous cell carcinoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vaginal / vulvar cancer, VIPpoma, and Wilm's tumor.In certain embodiments, tumors / cancers treated with one or more antibodies of the present disclosure include brain cancer, head and neck cancer, colorectal cancer, acute myeloid leukemia, pre-B cell acute lymphoblastic leukemia, bladder cancer, astrocytoma (preferably grade II, III or IV astrocytoma), glioblastoma, glioblastoma multiforme, small cell carcinoma and non-small cell carcinoma (preferably non-small cell lung cancer), lung adenocarcinoma, metastatic melanoma, androgen-independent metastatic prostate cancer, androgen-dependent metastatic prostate cancer, prostate adenocarcinoma and breast cancer, preferably ductal carcinoma and / or breast carcinoma. In certain embodiments, cancers treated with antibodies of the present disclosure include glioblastoma. In certain embodiments, cancers treated with one or more antibodies of the present disclosure include pancreatic cancer. In certain embodiments, cancers treated with one or more antibodies of the present disclosure include ovarian cancer. In certain embodiments, cancers treated with one or more antibodies of the present disclosure include lung cancer. In certain embodiments, cancers treated with one or more antibodies of the present disclosure include prostate cancer. In certain embodiments, the cancer treated with one or more antibodies of the present disclosure comprises colon cancer. In certain embodiments, the cancer treated comprises glioblastoma, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, or lung cancer. In certain embodiments, the cancer is refractory to other treatment methods. In certain embodiments, the cancer treated is recurrent.
[0313] In some embodiments, the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone, gallbladder cancer, or bile duct cancer. , Gestational Trophoblastic Disease, Germ Cell Tumor, Hematological Malignancies, Hepatocellular Carcinoma, Islet Cell Tumor, Kaposi's Sarcoma, Kidney Cancer, Lipoma / Benign Lipoma, Liposarcoma / Malignant Lipoma, Medulloblastoma, Meningioma, Merkel Cell Carcinoma, Multiple Endocrine Neoplasia, Multiple Myeloma, Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Tumor, Papillary Thyroid Carcinoma, Parathyroid Tumor, Pediatric Cancer, Peripheral Nerve Sheath Tumor, Pheochromocytoma, Pituitary Tumor, Prostate Cancer, Posterior Uveal Melanoma, Rare Hematological Disorders, Metastatic Kidney Cancer, Rhabdoid Tumor, Rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Gastric Cancer, Synovial Sarcoma, Testicular Cancer, Thymic Cancer, Thymoma, Thyroid Metastasis, Uterine Cancer, or any combination thereof.
[0314] In some instances, the cancer includes cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer, and neck cancer.
[0315] The compositions of the present disclosure can be administered at dosages, routes, and times determined in appropriate preclinical and clinical experiments and trials. The compositions can be administered multiple times at dosages within these ranges. The administration of the compositions can be combined with other useful methods for treating desired diseases or conditions determined by those skilled in the art. In certain embodiments, the antibodies can be administered to subjects in need thereof by any route suitable for administering pharmaceutical compositions containing antibodies, such as, for example, subcutaneously, intraperitoneally, intravenously, intramuscularly, intratumorally, or intracerebrally. In certain embodiments, the antibodies are administered intravenously. In certain embodiments, the antibodies are administered subcutaneously. In certain embodiments, the antibodies are administered intratumorally. In certain embodiments, the antibodies are administered on a suitable dosage schedule, for example, once a week, twice a week, once a month, twice a month, once every two weeks, once every three weeks, or once a month, etc. In certain embodiments, the antibodies are administered once every three weeks. The antibodies can be administered in any therapeutically effective amount. In certain embodiments, the therapeutically acceptable amount is between about 0.1 mg / kg and about 50 mg / kg. In certain embodiments, the therapeutically acceptable amount is between about 1 mg / kg and about 40 mg / kg. In certain embodiments, the therapeutically acceptable amount is between about 1 mg / kg and about 20 mg / kg. In certain embodiments, the therapeutically acceptable amount is between about 1 mg / kg and about 10 mg / kg. In certain embodiments, the therapeutically acceptable amount is between about 5 mg / kg and about 30 mg / kg. In certain embodiments, the therapeutically acceptable amount is between about 5 mg / kg and about 20 mg / kg. The therapeutically effective amount includes an amount sufficient to improve one or more symptoms associated with the disease to be treated or suffering.
[0316] For the purposes of the present disclosure, preventive, palliative, symptomatic and / or therapeutic treatments may represent different aspects of the present disclosure. The anti-cPD-1 antibodies or antigen-binding fragments thereof or scFv disclosed herein may be administered parenterally, such as intravenously, such as intramuscularly, such as subcutaneously. Alternatively, the antibodies of the present disclosure may be administered parenterally, such as orally or topically. The antibodies of the present disclosure may be administered prophylactically. The antibodies of the present disclosure may be administered therapeutically (as needed).
[0317] Pharmaceutical composition, kit and method for producing the composition
[0318] Also provided are pharmaceutical compositions comprising any of the binding polypeptides, scFvs, antibodies or antigen binding fragments disclosed herein. Compositions include pharmaceutical compositions and formulations for administration, such as for treating a disease or disorder. Also provided are therapeutic methods for administering the pharmaceutical compositions to a subject (e.g., a dog).
[0319] Pharmaceutical compositions and formulations generally include one or more optional pharmaceutically acceptable carriers or excipients. In some embodiments, the composition includes at least one additional therapeutic agent.
[0320] The term "pharmaceutical formulation" refers to a formulation in which the biological activity of the active ingredient contained therein is effective and does not contain additional ingredients that are unacceptably toxic to the subject to whom the formulation is administered. "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical formulation that is non-toxic to the subject other than the active ingredient. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives. In some aspects, the selection of the carrier depends in part on the specific composition and / or method of administration. Therefore, there are a variety of suitable formulations. For example, a pharmaceutical composition may contain a preservative. Suitable preservatives may include, for example, methyl paraben, propyl paraben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives may be used. The amount of the preservative or its mixture is generally about 0.0001% to about 2% by weight of the total composition. Carriers are described in, for example, Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethylammonium chloride; benzalkonium chloride; benzethonium chloride; chloride); phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, such as polyethylene glycol (PEG).
[0321] In some aspects, a buffer is included in the composition. Suitable buffers include citric acid, sodium citrate, phosphoric acid, potassium phosphate, and other various acids and salts. In some aspects, a mixture of two or more buffers is used. The amount of the buffer or its mixture is generally about 0.001% to about 4% by weight of the total composition. Methods for preparing an administrable pharmaceutical composition are known. For example, exemplary methods are described in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st edition (May 1, 2005).
[0322] The preparation may include an aqueous solution. The preparation or composition may also contain more than one active ingredient useful for a specific indication, disease or condition for the treatment of the composition, preferably those that are complementary to the activity of the composition, wherein the respective activities do not adversely affect each other. These active ingredients may be appropriately combined in an amount effective for the intended purpose. Therefore, in some embodiments, the pharmaceutical composition further includes other pharmaceutically active agents or drugs, such as chemotherapeutic agents, for example, asparaginase, busulfan, carboplatin, cisplatin, daunomycin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine and / or vincristine. In some embodiments, the pharmaceutical composition contains an amount that effectively treats or prevents a disease or condition, such as a therapeutically effective amount or a preventive effective amount of the composition. In some embodiments, the treatment or preventive effect is monitored by regularly evaluating the treated subject. The desired dosage can be achieved by administering the composition by a single push, multiple pushes, or a continuous infusion of the composition.
[0323] Preparations include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual or suppository administration. In some embodiments, the composition is administered parenterally. The term "parenteral" as used herein includes intravenous, intramuscular, subcutaneous, rectal, vaginal and peritoneal administration. In some embodiments, the composition is administered to the subject using a peripheral systemic administration method by intravenous, intraperitoneal or subcutaneous injection. In some embodiments, the composition is provided in a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion or viscous composition, which can be buffered to a selected pH value in some aspects. Liquid preparations are generally easier to prepare than gels, other viscous compositions and solid compositions. In addition, liquid preparations are more convenient to apply to a certain extent, particularly by injection. On the other hand, viscous compositions can be formulated within an appropriate viscosity range to provide a longer contact time with a specific tissue. Liquid or viscous compositions can include a carrier, which can be a solvent or dispersion medium containing, for example, water, saline, phosphate buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and a suitable mixture thereof.
[0324] Sterile injectable solutions can be prepared by incorporating the composition into a solvent, such as mixing with a suitable carrier, diluent or excipient, such as sterile water, saline, glucose, dextrose, etc. Based on the route of administration and the desired formulation, the composition may also contain auxiliary substances, such as wetting agents, dispersants or emulsifiers (e.g., methylcellulose), pH buffers, gelling agents or viscosity enhancing additives, preservatives, flavoring agents and / or pigments. In some respects, suitable formulations may be prepared with reference to standard texts.
[0325] Various additives may also be added to enhance the stability and sterility of the composition, including antimicrobial preservatives, antioxidants, chelating agents, and buffers. Prevention of the action of microorganisms may be ensured by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, and sorbic acid). Absorption of injectable pharmaceutical forms may be prolonged by the use of agents that delay absorption, such as aluminum monostearate and gelatin.
[0326] Preparations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.
[0327] The contents of the articles, patents, and patent applications mentioned or cited herein, and all other documents and information available in electronic form are incorporated herein by reference in their entirety to the same extent as if each individual publication was incorporated herein by reference. Applicants reserve the right to incorporate into this application any and all materials and information in any such articles, patents, patent applications, or other physical and electronic documents.
[0328] In certain embodiments, the anti-canine PD-1 antibody of the present disclosure is included in a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, carriers, and diluents. Pharmaceutically acceptable excipients, carriers, and diluents may be included to improve the shelf life, stability, or applicability of the antibody. Such compounds include salts, pH buffers, detergents, anticoagulants, and preservatives. In certain embodiments, the antibody of the present disclosure is suspended in a sterile solution for administration. In certain embodiments, the solution comprises about 0.9% NaCl. In certain embodiments, the solution comprises about 5.0% glucose. In certain embodiments, the solution further comprises one or more of the following: a buffer such as acetate, citrate, histidine, succinate, phosphate, bicarbonate, and hydroxymethylaminomethane (Tris); a surfactant such as polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), and poloxamer 188; a polyol / disaccharide / polysaccharide such as glucose, dextrose, mannose, mannitol, sorbitol, sucrose, trehalose, and dextran 40; an amino acid such as glycine or arginine; an antioxidant such as ascorbic acid, methionine; or a chelating agent such as EDTA or EGTA.
[0329] In certain embodiments, the antibodies of the present disclosure can be freeze-dried for transportation / storage, and reconstituted before administration. In certain embodiments, the freeze-dried antibody formulation includes a bulking agent, such as mannitol, sorbitol, sucrose, trehalose, dextran 40 or a combination thereof. The freeze-dried formulation can be contained in a vial consisting of glass or other suitable non-reactive materials. When formulated (whether reconstituted or not), the antibody can be buffered at a certain pH that is usually less than 7.0. In certain embodiments, the pH can be between 4.5 and 7.0, 4.5 and 6.5, 4.5 and 6.0, 4.5 and 5.5, 4.5 and 5.0 or 5.0 and 6.0.
[0330] Also described herein are kits comprising one or more antibodies described herein in an appropriate container, and one or more additional components selected from the group consisting of: instructions for use; diluents, excipients, carriers, and administration devices.
[0331] In certain embodiments, described herein is a method for making a composition for treating cancer, sepsis or septic shock, or chronic infection (such as viral infection), comprising mixing one or more pharmaceutically acceptable excipients, carriers or diluents with an antibody of the disclosure. In certain embodiments, described herein is a method for preparing a cancer therapeutic for storage or transport, comprising lyophilizing one or more antibodies of the disclosure.
[0332] Although the present disclosure has been described with reference to its specific embodiments, it will be appreciated by those skilled in the art that various changes may be made without departing from the true spirit and scope of the present disclosure, and that equivalents may be used to replace them. It will be apparent to those skilled in the art that other appropriate modifications and adjustments may be made to the methods described herein using appropriate equivalents without departing from the scope of the embodiments disclosed herein. In addition, many modifications may be made to adapt specific circumstances, materials, compositions of matter, processes, one or more process steps to the goals, spirit and scope of the present disclosure. All of these modifications are within the scope of the appended claims. Having now described certain embodiments of the present invention in detail, the present invention may be more clearly understood by reference to the following examples.
[0333] Example
[0334] The present disclosure will be described in further detail by reference to the following experimental examples. These examples are provided for the purpose of illustration only and are not limiting unless otherwise stated. Therefore, the present disclosure should never be interpreted as being limited to the following examples, but should be interpreted as including any and all variations that become apparent due to the teachings provided herein. Although preferred embodiments of the present invention have been shown and described herein, it is apparent to those skilled in the art that such embodiments are provided only by way of example. Without departing from the present disclosure, those skilled in the art may also make many changes, modifications and substitutions. It should be understood that in implementing the present disclosure, various alternatives to the embodiments of the present disclosure described herein may be adopted.
[0335] All publications, patent applications, issued patents, and other documents mentioned in this specification are incorporated herein by reference, as if each individual publication, patent application, issued patent, or other document was specifically and individually incorporated by reference in its entirety. Definitions contained in text incorporated by reference are excluded if they conflict with definitions in this disclosure.
[0336] Without further description, it is believed that one of ordinary skill in the art can use the preceding description and the following illustrative examples to make and use the compounds of the present disclosure and to practice the claimed methods. Thus, the following working examples specifically point out some embodiments of the present disclosure.
[0337] Example 1: Generation of Canine Anti-Canine PD-1 scFv
[0338] As previously described, a canine IgM / IgG / l / k scFv phage display library containing approximately 40 billion individual E. coli transformants was constructed from canine B cell mRNA and pComb3X phagemid vectors using oligonucleotide primers based on published canine immunoglobulin heavy and light chain germline genes (Andris-Widhopf, J., Steinberger, P., Fuller, R., Rader, C., Barbas, CF Generation of antibody libraries: PCR amplification and assembly of light-and heavy-chain coding sequences in Barbas, CF, Burton, DR, Scott, JK, Silverman GJPhage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001) and Lefranc, MP et al., IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37, D1006-1012 (2009)). Aliquots of this library were subjected to four rounds of solid phase screening (“panning”) against canine PD-1. To verify that the screened phage contained cPD-1-specific scFv phage particles, polyclonal scFv phage from each round of panning were evaluated by scFv phage ELISA using cPD-1 as the target antigen ( Figure 1 A large number of phages enriched for cPD-1 specific binders were found in the third round of panning (P3) and increased in the fourth round of panning (P4).
[0339] A preliminary survey of the positive hits was evaluated by testing their ability to bind to cPD-1 by phage ELISA. 10 / 16 clones from P3 and 15 / 16 clones from P4 bound to cPD-1 with a distinct range of affinities ( Figure 2A-2B ). From these 25 binders, 14 unique clones were identified by nucleotide sequencing and made into soluble scFv for further characterization ( Figure 3 left).
[0340] After this initial survey yielded a positive rate, several hundred additional clones were subjected to high-throughput screening. 176 positive clones were isolated, of which 8 unique clones were further identified. Five of these 8 clones were made into soluble scFv for further characterization. Based on the results of soluble scFv binding to cPD-1 ( Figure 3 ), clones 3-4, 3-8, 3-13, 4-2, 4-9, 4-14, P4B1, P3C6, and P4F3 were screened to further analyze their ability to inhibit the interaction between PD-1 and PD-L1 ( Figure 4 ).
[0341] Five clones were detected that showed evidence of their ability to inhibit the interaction between PD-1 and PD-L1 (e.g. Figure 4 These clones were then tested for their ability to bind to membrane-expressed cPD-1. The human erythroleukemia cell line K562, edited to remove CD32 (KTδ32) (to reduce nonspecific binding), was engineered to express cPD-1 using a retroviral vector carrying a puromycin selection cassette (KTδ32.cPD-1). Figure 4 ) The selected HA-tagged soluble scFvs were incubated with KTδ32 or KTδ32.cPD-1 cells, and the binding was determined using anti-HA antibody and flow cytometry ( Figure 5 ).
[0342] Clones P3C6 and P4B1, which inhibit PD-1:PD-L1 protein interaction and bind to PD-1 expressed on the cell surface, were reformatted into full-length canine IgG4 molecules and tested again for their ability to bind to cell surface PD-1 by flow cytometry ( Figure 6 ).
[0343] The yield of P3C6 obtained by transient transfection of 293T cells was low, and chain exchange experiments confirmed that this was related to the VH chain of P3C6 (data not shown). Strategic amino acid substitutions were performed, and the resulting mutant VH chains were paired with the original P3C6 light chain and evaluated for yield and cPD-1 binding ability ( Figure 7 and Figure 8 Initial attempts to mutate P3C6 also resulted in low yields ( Fig. 9A After many attempts, two specific mutants (P3C6 mut 3.1 and mut 3.2) showed significantly improved yields ( Fig. 9B ).
[0344] To determine whether the P3C6 mutant could increase the proliferation and IFNγ production of canine T cells, canine PBMCs were labeled with Cell TraceViolet (CTV) and stimulated with the mitogen concanavalin A in the presence of the P3C6 mutant IgG4 molecules. At 96 hours after stimulation, the proliferation of CD5+ T cells was measured by flow cytometry ( Fig.10 ), and the production of IFNγ was measured by ELISA ( Fig.11 ).
[0345] Given the relatively low number of unique scFvs identified from the initial screen and subsequent high-throughput screens, a second high-throughput screen was performed, screening 872 clones and identifying over 200 soluble scFv clones present in expression extracts that bound to cPD-1 by ELISA. Binding of these clones was further evaluated by flow cytometry, and 3 additional unique scFv clones were found to bind to cPD-1 on the surface of KTδ32 cells. Only one of these clones from round 3 of panning, clone A6, was successfully reformatted into full-length canine IgG4. The ability of this full-length clone to specifically bind to membrane-bound cPD-1 was evaluated in flow cytometry ( Fig.12 ). Clone A6 bound specifically to KTδ32.cPD-1 cells, and this binding was blocked by preincubation of soluble cPD-1 with IgG4 molecules.
[0346] Examples of implementation methods
[0347] The following enumerated embodiments are provided, and their numbering is not to be construed as designating their importance.
[0348] Embodiment 1 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0349] a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, 27 or 43,
[0350] a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, 28 or 44,
[0351] a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, 29 or 45,
[0352] a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, 30 or 46,
[0353] a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, 31 or 47, and
[0354] A light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 6, 32 or 48.
[0355] Embodiment 2 provides the antibody or antigen-binding fragment thereof of embodiment 1, wherein the antibody or antigen-binding fragment thereof comprises:
[0356] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and
[0357] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
[0358] Embodiment 3 provides the antibody or antigen-binding fragment thereof of embodiment 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises:
[0359] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and
[0360] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0361] Embodiment 4 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0362] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and
[0363] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
[0364] Embodiment 5 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0365] A heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and
[0366] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
[0367] Embodiment 6 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0368] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and
[0369] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0370] Embodiment 7 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0371] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and
[0372] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
[0373] Embodiment 8 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0374] a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1,
[0375] a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2,
[0376] a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3,
[0377] a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4,
[0378] a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, and
[0379] The light chain complementarity determining region 3 (LCDR3) comprises the amino acid sequence set forth in SEQ ID NO:6.
[0380] Embodiment 9 provides the antibody or antigen-binding fragment thereof of embodiment 8, wherein the antibody or antigen-binding fragment thereof comprises:
[0381] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and
[0382] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:11.
[0383] Embodiment 10 provides the antibody or antigen-binding fragment thereof of embodiment 8 or 9, wherein the antibody or antigen-binding fragment thereof comprises:
[0384] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and
[0385] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:25.
[0386] Embodiment 11 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0387] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and
[0388] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:11.
[0389] Embodiment 12 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0390] a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7; and
[0391] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:11.
[0392] Embodiment 13 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0393] a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9; and
[0394] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:11.
[0395] Embodiment 14 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0396] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and
[0397] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:25.
[0398] Embodiment 15 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0399] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, and
[0400] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:25.
[0401] Embodiment 16 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0402] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21, and
[0403] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:25.
[0404] Embodiment 17 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0405] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 23, and
[0406] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:25.
[0407] Embodiment 18 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0408] a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 27,
[0409] a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 28,
[0410] a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 29,
[0411] a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 30,
[0412] a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 31, and
[0413] The light chain complementarity determining region 3 (LCDR3) comprises the amino acid sequence set forth in SEQ ID NO:32.
[0414] Embodiment 19 provides the antibody or antigen-binding fragment thereof of embodiment 18, wherein the antibody or antigen-binding fragment thereof comprises:
[0415] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:33; and
[0416] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:35.
[0417] Embodiment 20 provides the antibody or antigen-binding fragment thereof of embodiment 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises:
[0418] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39, and
[0419] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:41.
[0420] Embodiment 21 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0421] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:33; and
[0422] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:35.
[0423] Embodiment 22 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0424] a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 33; and
[0425] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:35.
[0426] Embodiment 23 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0427] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39, and
[0428] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:41.
[0429] Embodiment 24 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0430] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 39, and
[0431] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:41.
[0432] Embodiment 25 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0433] a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 43,
[0434] a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 44,
[0435] a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 45,
[0436] a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 46,
[0437] a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 47, and
[0438] The light chain complementarity determining region 3 (LCDR3) comprises the amino acid sequence set forth in SEQ ID NO:48.
[0439] Embodiment 26 provides the antibody or antigen-binding fragment thereof of embodiment 25, wherein the antibody or antigen-binding fragment thereof comprises:
[0440] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:49; and
[0441] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:51.
[0442] Embodiment 27 provides the antibody or antigen-binding fragment thereof of embodiment 25 or 26, wherein the antibody or antigen-binding fragment thereof comprises:
[0443] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 55, and
[0444] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:57.
[0445] Embodiment 28 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0446] a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:49; and
[0447] A light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:51.
[0448] Embodiment 29 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0449] a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 49; and
[0450] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:51.
[0451] Embodiment 30 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0452] An immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 55, and
[0453] An immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:57.
[0454] Embodiment 31 provides an antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or the antigen-binding fragment thereof comprises:
[0455] An immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 55, and
[0456] An immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:57.
[0457] Embodiment 32 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-31, wherein the antibody or antigen-binding fragment thereof is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these.
[0458] Embodiment 33 provides the antibody or antigen-binding fragment thereof described in any one of embodiments 1-32, wherein the antibody or antigen-binding fragment thereof is selected from a full-length antibody, Fab, a single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a diabody.
[0459] Embodiment 34 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-33, wherein the antibody is a full-length antibody.
[0460] Embodiment 35 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-34, wherein the antibody is a canine antibody or a caninized antibody.
[0461] Embodiment 36 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-35, wherein the antibody is a canine antibody.
[0462] Embodiment 37 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-33, wherein the antigen-binding fragment is a scFv.
[0463] Embodiment 38 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-37, wherein specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0464] Embodiment 39 provides a canine antibody or an antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1).
[0465] Embodiment 40 provides a canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-36.
[0466] Embodiment 41 provides the canine antibody or antigen-binding fragment thereof of embodiment 39 or 40, wherein specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death-ligand 1).
[0467] Embodiment 42 provides a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising:
[0468] a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2 and HCDR3, wherein HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 27 and 43, HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 28 and 44, and HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 29 and 45; and
[0469] a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 30 and 46, LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 31 and 47, and LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 32 and 48,
[0470] wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0471] Embodiment 43 provides a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising:
[0472] A heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and
[0473] A light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51,
[0474] wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0475] Embodiment 44 provides a single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), which includes the amino acid sequence listed in SEQ ID NO: 13, 15, 17, 37 or 53.
[0476] Embodiment 45 provides the scFv of any one of embodiments 42-44, wherein specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0477] Embodiment 46 provides a bispecific molecule comprising the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45 linked to a molecule having a second binding specificity.
[0478] Embodiment 47 provides an immunoconjugate comprising the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, or the bispecific molecule of embodiment 46 linked to a therapeutic agent.
[0479] Embodiment 48 provides an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45.
[0480] Embodiment 49 provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof comprises:
[0481] A heavy chain variable region encoded by a nucleic acid comprising a polynucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and
[0482] A light chain variable region encoded by a nucleic acid comprising a polynucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52.
[0483] Embodiment 50 provides the isolated nucleic acid of embodiment 49, wherein the heavy chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50.
[0484] Embodiment 51 provides the isolated nucleic acid of embodiment 49 or 50, wherein the light chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52.
[0485] Embodiment 52 provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising:
[0486] a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 8; and
[0487] The light chain variable region is encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO:12.
[0488] Embodiment 53 provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising:
[0489] a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 10; and
[0490] The light chain variable region is encoded by a nucleic acid sequence comprising the polynucleotide sequence listed in SEQ ID NO:12.
[0491] Embodiment 54 provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising:
[0492] a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 34; and
[0493] The light chain variable region is encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:36.
[0494] Embodiment 55 provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising:
[0495] a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 50; and
[0496] The light chain variable region is encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:52.
[0497] Embodiment 56 provides the isolated nucleic acid of any one of embodiments 49-55, wherein the antibody or antigen-binding fragment thereof is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these.
[0498] Embodiment 57 provides the isolated nucleic acid of any one of embodiments 49-56, wherein the antibody or antigen-binding fragment thereof is selected from a full-length antibody, Fab, a single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a diabody.
[0499] Embodiment 58 provides the isolated nucleic acid of any one of embodiments 49-57, wherein the antibody is a full-length antibody.
[0500] Embodiment 59 provides the isolated nucleic acid of any one of embodiments 49-58, wherein the antibody is a canine antibody or a caninized antibody.
[0501] Embodiment 60 provides the isolated nucleic acid of any one of embodiments 49-59, wherein the antibody is a canine antibody.
[0502] Embodiment 61 provides an isolated nucleic acid encoding a single-chain variable fragment (scFv), comprising:
[0503] A heavy chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and
[0504] A light chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 12, 36 or 52,
[0505] wherein the heavy chain variable region and the light chain variable region are connected by a linker.
[0506] Embodiment 62 provides an isolated nucleic acid encoding a single-chain variable fragment (scFv), which comprises a polynucleotide sequence listed in SEQ ID NO: 14, 16, 18, 38 or 54.
[0507] Embodiment 63 provides the isolated nucleic acid of any one of embodiments 49-62, wherein the antibody or antigen-binding fragment thereof or the scFv specifically binds to canine programmed death protein 1 (cPD-1).
[0508] Embodiment 64 provides the isolated nucleic acid of embodiment 56, wherein specific binding of the antibody or antigen-binding fragment thereof or the scFv to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
[0509] Embodiment 65 provides a vector comprising the isolated nucleic acid of any one of embodiments 48-64.
[0510] Embodiment 66 provides the vector described in embodiment 65, wherein the vector is an expression vector.
[0511] Embodiment 67 provides the vector of embodiment 65 or 66, wherein the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, and a retroviral vector.
[0512] Embodiment 68 provides a host cell comprising the isolated nucleic acid of any one of embodiments 48-64 or the vector of any one of embodiments 65-67.
[0513] Embodiment 69 provides the host cell of embodiment 68, wherein the host cell is of eukaryotic or prokaryotic origin.
[0514] Embodiment 70 provides the host cell of embodiment 68 or 69, wherein the host cell is of mammalian origin.
[0515] Embodiment 71 provides the host cell of embodiment 68 or 69, wherein the host cell is of bacterial origin.
[0516] Embodiment 72 provides the host cell of any one of embodiments 68-70, wherein the host cell is a Chinese hamster ovary cell.
[0517] Embodiment 73 provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in any one of embodiments 1-38, the canine antibody described in any one of embodiments 39-41, or the scFv described in any one of embodiments 42-45, the bispecific molecule described in embodiment 46, or the immunoconjugate described in embodiment 47, and a pharmaceutically acceptable excipient, carrier, or diluent.
[0518] Embodiment 74 provides the pharmaceutical composition of embodiment 73 formulated for intravenous administration.
[0519] Embodiment 75 provides the pharmaceutical composition of embodiment 73, which is formulated for subcutaneous administration.
[0520] Embodiment 76 provides the pharmaceutical composition of embodiment 73, which is formulated for intratumoral administration.
[0521] Embodiment 77 provides a kit comprising the antibody or antigen-binding fragment thereof described in any one of embodiments 1-38, the canine antibody described in any one of embodiments 39-41, or the scFv described in any one of embodiments 42-45, the bispecific molecule described in embodiment 46, the immunoconjugate described in embodiment 47, or the pharmaceutical composition described in embodiment 73, and instructions for use.
[0522] Embodiment 78 provides a method of increasing T cell proliferation and reducing T cell exhaustion in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof of any one of embodiments 1-38, a canine antibody of any one of embodiments 39-41, or a scFv of any one of embodiments 42-45, a bispecific molecule of embodiment 46, or an immunoconjugate of embodiment 47, or a pharmaceutical composition of embodiment 73.
[0523] Embodiment 79 provides a method of increasing IFNγ production in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, or the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73.
[0524] Embodiment 80 provides a method of inhibiting the canine programmed death protein 1 (cPD-1) signaling pathway in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, or the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73.
[0525] Embodiment 81 provides the method of any one of embodiments 78-80, wherein the subject has cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0526] Embodiment 82 provides a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof of any of embodiments 1-38, the canine antibody of any of embodiments 39-41, or the scFv of any of embodiments 42-45, the bispecific molecule of embodiment 46, or the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73.
[0527] Embodiment 83 provides the method of embodiment 82, wherein the disease or condition comprises cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0528] Embodiment 84 provides the method of any one of embodiments 78-83, further comprising administering one or more additional therapies (eg, chemotherapy) or interventions.
[0529] Embodiment 85 provides the method of any one of embodiments 81, 83 or 84, wherein the cancer is associated with the canine programmed death protein 1 (cPD-1) signaling pathway.
[0530] Embodiment 86 provides the method of embodiment 85, wherein a ligand for cPD-1 (e.g., canine programmed death ligand 1) is expressed on a cancer cell in the subject.
[0531] Embodiment 87 provides the method of any one of embodiments 80-86, wherein cPD-1 is expressed on immune cells of the subject.
[0532] Embodiment 88 provides the method of embodiment 87, wherein the immune cell comprises a T cell (e.g., an activated T cell), a B cell, a natural killer (NK) cell, a regulatory T cell, a macrophage, a dendritic cell (DC), or a tumor infiltrating lymphocyte.
[0533] Embodiment 89 provides the method of any of embodiments 81-88, wherein the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibroblastoma of bone Dysplasia, Gallbladder or Bile Duct Cancer, Gestational Trophoblastic Disease, Germ Cell Tumors, Hematologic Malignancies, Hepatocellular Carcinoma, Islet Cell Tumors, Kaposi's Sarcoma, Kidney Cancer, Lipoma / Benign Lipoma, Liposarcoma / Malignant Lipoma, Medulloblastoma, Meningioma, Merkel Cell Carcinoma, Multiple Endocrine Neoplasia, Multiple Myeloma, Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Tumors, Papillary Thyroid Carcinoma, Parathyroid Tumor, Pediatric Cancer, Peripheral Nerve Sheath Tumor, Pheochromocytoma, Pituitary Tumor, Prostate Cancer, Posterior Uveal Melanoma, Rare Hematologic Disorders, Metastatic Kidney Cancer, Rhabdoid Tumor, Rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Gastric Cancer, Synovial Sarcoma, Testicular Cancer, Thymic Cancer, Thymoma, Metastatic Thyroid Cancer, Uterine Cancer, or any combination thereof.
[0534] Embodiment 90 provides the method of any one of embodiments 81-88, wherein the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer and neck cancer.
[0535] Embodiment 91 provides the method of any of embodiments 78-90, wherein the antibody or antigen-binding fragment thereof, the canine antibody, the scFv, the bispecific molecule, or the immunoconjugate specifically binds to cPD-1.
[0536] Embodiment 92 provides the method of embodiment 91, wherein binding of the antibody or antigen-binding fragment thereof, the canine antibody, the scFv, the bispecific molecule, or the immunoconjugate to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death-ligand 1).
[0537] Embodiment 93 provides the method of any one of embodiments 78-92, wherein the subject is a canine.
[0538] Embodiment 94 provides a method for manufacturing the pharmaceutical composition of embodiment 73, comprising mixing the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41 or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, or the immunoconjugate of embodiment 47 and a pharmaceutically acceptable excipient, carrier or diluent.
[0539] Embodiment 95 provides a method for making a composition for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection), comprising mixing the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, or the immunoconjugate of embodiment 47 and a pharmaceutically acceptable excipient, carrier, or diluent.
[0540] Embodiment 96 provides the method of embodiment 95, wherein the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone , Gallbladder or bile duct cancer, Gestational trophoblastic disease, Germ cell tumors, Hematologic malignancies, Hepatocellular carcinoma, Islet cell tumors, Kaposi's sarcoma, Kidney cancer, Lipoma / benign lipoma, Liposarcoma / malignant lipoma, Medulloblastoma, Meningioma, Merkel cell carcinoma, Multiple endocrine neoplasia, Multiple myeloma, Myelodysplastic syndrome, Neuroblastoma, Neuroendocrine tumors, Papillary thyroid carcinoma, Parathyroid tumor, Pediatric cancer, Peripheral nerve sheath tumor, Pheochromocytoma, Pituitary tumor, Prostate cancer, Posterior uveal melanoma, Rare hematologic disorders, Metastatic renal cancer, Rhabdoid tumor, Rhabdomyosarcoma, Sarcoma, Soft tissue sarcoma, Squamous cell carcinoma, Gastric cancer, Synovial sarcoma, Testicular cancer, Thymic carcinoma, Thymoma, Metastatic thyroid cancer, Uterine cancer, or any combination thereof.
[0541] Embodiment 97 provides the method described in embodiment 95, wherein the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer and neck cancer.
[0542] Embodiment 98 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73 for use as a medicament.
[0543] Embodiment 99 provides the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73 for use as a medicament for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0544] Embodiment 100 provides the use of the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the bispecific molecule of embodiment 46, the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73 for the manufacture of a medicament.
[0545] Embodiment 101 provides the use of the antibody or antigen-binding fragment thereof of any of embodiments 1-38, the canine antibody of any of embodiments 39-41, or the scFv of any of embodiments 42-45, the bispecific molecule of embodiment 46, the immunoconjugate of embodiment 47, or the pharmaceutical composition of embodiment 73 for the manufacture of a medicament for treating cancer, sepsis or septic shock, or a chronic infection (e.g., a viral infection).
[0546] Embodiment 102 provides a method for producing the antibody or antigen-binding fragment thereof of any one of embodiments 1-38, the canine antibody of any one of embodiments 39-41, or the scFv of any one of embodiments 42-45, the method comprising culturing the host cell of any one of embodiments 68-72.
[0547] Embodiment 103 provides the method of embodiment 102, further comprising incubating the host cell of any of embodiments 68-72 in a cell culture medium under conditions sufficient to allow expression and secretion of the antibody or antigen-binding fragment thereof of any of embodiments 1-38, the canine antibody of any of embodiments 39-41, or the scFv of any of embodiments 42-45.
[0548] Other Implementations
[0549] The recitation of a list of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of the listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0550] The disclosure of each patent, patent application, and publication cited herein is incorporated herein by reference in its entirety. Although the disclosure has been disclosed with reference to specific embodiments, it is apparent that other persons skilled in the art may conceive of other embodiments and variations of the disclosure without departing from the true spirit and scope of the disclosure. The appended claims are intended to be interpreted as including all such embodiments and equivalent variations.
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, 27 or 43, (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, 28 or 44, (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, 29 or 45, (d) a light chain complementary determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, 30 or 46, (e) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, 31 or 47, and (f) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 6, 32 or 48.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
4. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
5. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51.
6. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
7. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, 21, 23, 39 or 55, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO: 25, 41 or 57.
8. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 2, (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 3, (d) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, (e) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 5, and (f) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO:
6.
9. The antibody or antigen-binding fragment thereof according to claim 8, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
11.
10. The antibody or antigen-binding fragment thereof according to claim 8 or 9, wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
25.
11. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or 9; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
11.
12. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
11.
13. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
11.
14. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, 21 or 23, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
25.
15. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
25.
16. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
25.
17. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 23, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
25.
18. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 27, (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 28, (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 29, (d) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 30, (e) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 31, and (f) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO:
32.
19. The antibody or antigen-binding fragment thereof according to claim 18, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:33; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
35.
20. The antibody or antigen-binding fragment thereof according to claim 18 or 19, wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
41.
21. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:33; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
35.
22. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 33; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
35.
23. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO: 39, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
41.
24. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 39, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
41.
25. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 43, (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 44, (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 45, (d) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 46, (e) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 47, and (f) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO:
48.
26. The antibody or antigen-binding fragment thereof according to claim 25, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:49; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
51.
27. The antibody or antigen-binding fragment thereof according to claim 25 or 26, wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:55, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
57.
28. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:49; and (b) a light chain variable region comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
51.
29. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 49; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
51.
30. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:55, and (b) an immunoglobulin light chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in SEQ ID NO:
57.
31. An antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), wherein the antibody or antigen-binding fragment thereof comprises: (a) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 55, and (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
57.
32. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 31, wherein the antibody or antigen-binding fragment thereof is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these.
33. The antibody or antigen-binding fragment thereof according to any one of claims 1-32, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of full-length antibody, Fab, single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and diabody.
34. The antibody or antigen-binding fragment thereof according to any one of claims 1-33, wherein the antibody is a full-length antibody.
35. The antibody or antigen-binding fragment thereof according to any one of claims 1-34, wherein the antibody is a canine antibody or a caninized antibody.
36. The antibody or antigen-binding fragment thereof according to any one of claims 1-35, wherein the antibody is a canine antibody.
37. The antibody or antigen-binding fragment thereof according to any one of claims 1-33, wherein the antigen-binding fragment is a scFv.
38. The antibody or antigen-binding fragment thereof according to any one of claims 1-37, wherein the specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with the ligand of cPD-1 (canine programmed death ligand 1).
39. A canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1).
40. A canine antibody or antigen-binding fragment thereof that specifically binds to canine programmed death protein 1 (cPD-1), comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-36.
41. The canine antibody or antigen-binding fragment thereof according to claim 39 or 40, wherein specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death-ligand 1).
42. A single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising: (a) a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2 and HCDR3, wherein HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 27 and 43, HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 28 and 44, and HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 29 and 45; and (b) a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 30 and 46, LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 31 and 47, and LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 32 and 48, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
43. A single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, 9, 33 or 49; and (b) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11, 35 or 51, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
44. A single-chain variable fragment (scFv) that specifically binds to canine programmed death protein 1 (cPD-1), comprising the amino acid sequence listed in SEQ ID NO: 13, 15, 17, 37 or 53.
45. The scFv of any one of claims 42-44, wherein specific binding of the antibody or antigen-binding fragment thereof to cPD-1 disrupts the interaction of cPD-1 with the ligand of cPD-1 (canine programmed death ligand 1).
46. A bispecific molecule comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, linked to a molecule having a second binding specificity.
47. An immunoconjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, or the bispecific molecule according to claim 46, linked to a therapeutic agent.
48. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45.
49. An isolated nucleic acid encoding an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region encoded by a nucleic acid comprising a polynucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and (b) a light chain variable region encoded by a nucleic acid comprising a polynucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to the polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52.
50. The isolated nucleic acid of claim 49, wherein the heavy chain variable region is encoded by a nucleic acid comprising the polynucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50.
51. The isolated nucleic acid of claim 49 or 50, wherein the light chain variable region is encoded by a nucleic acid comprising a polynucleotide sequence set forth in SEQ ID NO: 12, 36 or 52.
52. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: (a) a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 8; and (b) a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:
12.
53. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: (a) a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 10; and (b) a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:
12.
54. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: (a) a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 34; and (b) a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:
36.
55. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof, comprising: (a) a heavy chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO: 50; and (b) a light chain variable region encoded by a nucleic acid sequence comprising the polynucleotide sequence set forth in SEQ ID NO:
52.
56. An isolated nucleic acid according to any one of claims 49-55, wherein the antibody or antigen-binding fragment thereof is an IgG, IgM, IgE, IgA or IgD molecule, or is derived from one of these.
57. The isolated nucleic acid of any one of claims 49-56, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a full-length antibody, Fab, a single-chain variable fragment (scFv), sc(Fv)2, dsFv, Fab, Fab', (Fab')2, and a diabody.
58. The isolated nucleic acid of any one of claims 49-57, wherein the antibody is a full-length antibody.
59. The isolated nucleic acid of any one of claims 49-58, wherein the antibody is a canine antibody or a caninized antibody.
60. The isolated nucleic acid of any one of claims 49-59, wherein the antibody is a canine antibody.
61. An isolated nucleic acid encoding a single-chain variable fragment (scFv), comprising: (a) a heavy chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 8, 10, 34 or 50; and (b) a light chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 12, 36 or 52, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
62. An isolated nucleic acid encoding a single-chain variable fragment (scFv) comprising the polynucleotide sequence set forth in SEQ ID NO: 14, 16, 18, 38 or 54.
63. The isolated nucleic acid of any one of claims 49-62, wherein the antibody or antigen-binding fragment thereof or the scFv specifically binds to canine programmed death protein 1 (cPD-1).
64. The isolated nucleic acid of claim 56, wherein specific binding of the antibody or antigen-binding fragment thereof or the scFv to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death ligand 1).
65. A vector comprising the isolated nucleic acid according to any one of claims 48-64.
66. The vector of claim 65, wherein the vector is an expression vector.
67. The vector of claim 65 or 66, wherein the vector is selected from the group consisting of a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, and a retroviral vector.
68. A host cell comprising the isolated nucleic acid according to any one of claims 48-64 or the vector according to any one of claims 65-67.
69. The host cell of claim 68, wherein the host cell is of eukaryotic or prokaryotic origin.
70. The host cell of claim 68 or 69, wherein the host cell is of mammalian origin.
71. A host cell according to claim 68 or 69, wherein the host cell is of bacterial origin.
72. The host cell of any one of claims 68-70, wherein the host cell is a Chinese hamster ovary cell.
73. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, or the immunoconjugate according to claim 47, and a pharmaceutically acceptable excipient, carrier, or diluent.
74. The pharmaceutical composition of claim 73, formulated for intravenous administration.
75. The pharmaceutical composition of claim 73, formulated for subcutaneous administration.
76. The pharmaceutical composition of claim 73, formulated for intratumoral administration.
77. A kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, the immunoconjugate according to claim 47, or the pharmaceutical composition according to claim 73, and instructions for use.
78. A method of increasing T cell proliferation and reducing T cell exhaustion in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a canine antibody according to any one of claims 39-41, or a scFv according to any one of claims 42-45, a bispecific molecule according to claim 46, or an immunoconjugate according to claim 47, or a pharmaceutical composition according to claim 73.
79. A method of increasing IFNγ production in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a canine antibody according to any one of claims 39-41, or a scFv according to any one of claims 42-45, a bispecific molecule according to claim 46, or an immunoconjugate according to claim 47, or a pharmaceutical composition according to claim 73.
80. A method of inhibiting the canine programmed death protein 1 (cPD-1) signaling pathway in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a canine antibody according to any one of claims 39-41, or a scFv according to any one of claims 42-45, a bispecific molecule according to claim 46, or an immunoconjugate according to claim 47, or a pharmaceutical composition according to claim 73.
81. The method of any one of claims 78-80, wherein the subject has cancer, sepsis or septic shock, or a chronic infection.
82. A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a canine antibody according to any one of claims 39-41, or a scFv according to any one of claims 42-45, a bispecific molecule according to claim 46, or an immunoconjugate according to claim 47, or a pharmaceutical composition according to claim 73.
83. The method of claim 82, wherein the disease or condition comprises cancer, sepsis or septic shock, or a chronic infection.
84. The method of any one of claims 78-83, further comprising administering one or more additional therapies or interventions.
85. The method of any one of claims 81, 83, or 84, wherein the cancer is associated with the canine programmed death protein 1 (cPD-1) signaling pathway.
86. The method of claim 85, wherein the ligand for cPD-1 (canine programmed death ligand 1) is expressed on cancer cells of the subject.
87. The method of any one of claims 80-86, wherein cPD-1 is expressed on immune cells of the subject.
88. The method of claim 87, wherein the immune cells comprise T cells, B cells, natural killer (NK) cells, regulatory T cells, macrophages, dendritic cells (DCs), or tumor infiltrating lymphocytes.
89. The method of any one of claims 81-88, wherein the cancer comprises melanoma, prostate cancer, head and neck cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma, adrenal cancer, AIDS-related cancer, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumor, carotid body tumor, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraosseous myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone, gallbladder cancer or bile duct cancer, gestational trophoblastic disease, germ cell tumor, hematopoietic stem cell carcinoma, fluid malignancies, hepatocellular carcinoma, islet cell tumors, Kaposi's sarcoma, renal cancer, lipoma / benign lipoma, liposarcoma / malignant lipoma, medulloblastoma, meningioma, Merkel cell carcinoma, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, papillary thyroid carcinoma, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pheochromocytoma, pituitary tumor, prostate cancer, posterior uveal melanoma, rare hematologic disorders, renal metastasis, rhabdoid tumor, rhabdomyosarcoma, sarcoma, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastasis, uterine cancer, or any combination thereof.
90. The method of any one of claims 81-88, wherein the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer, and neck cancer.
91. The method of any one of claims 78-90, wherein the antibody or antigen-binding fragment thereof, the canine antibody, the scFv, the bispecific molecule, or the immunoconjugate specifically binds to cPD-1.
92. The method of claim 91, wherein binding of the antibody or antigen-binding fragment thereof, the canine antibody, the scFv, the bispecific molecule, or the immunoconjugate to cPD-1 disrupts the interaction of cPD-1 with a ligand of cPD-1 (e.g., canine programmed death-ligand 1).
93. The method of any one of claims 78-92, wherein the subject is a canine.
94. A method of making a pharmaceutical composition according to claim 73, comprising mixing the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, or the immunoconjugate according to claim 47 and a pharmaceutically acceptable excipient, carrier or diluent.
95. A method of making a composition for treating cancer, sepsis or septic shock, or chronic infection, comprising mixing the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, or the immunoconjugate according to claim 47 and a pharmaceutically acceptable excipient, carrier or diluent.
96. The method of claim 95, wherein the cancer comprises melanoma (e.g., metastatic malignant melanoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), head and neck cancer (e.g., squamous cell carcinoma of the head and neck), cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma (e.g., B-cell lymphoma), adrenal cancer, AIDS-related cancers, alveolar soft tissue sarcoma, astrocytoma, bone cancer, brain cancer and spinal cord cancer, metastatic brain tumors, carotid body tumors, chondroma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, benign fibrous histiocytoma of the skin, desmoplastic small round cell tumor, ependymoma, Ewing's tumor, extraskeletal myxoid chondroma, fibrous dysplasia of bone, fibrous dysplasia of bone, cholangiocarcinoma, Cyst or bile duct cancer, gestational trophoblastic disease, germ cell tumors, hematological malignancies, hepatocellular carcinoma, islet cell tumors, Kaposi's sarcoma, renal cancer, lipoma / benign lipoma, liposarcoma / malignant lipoma, medulloblastoma, meningioma, Merkel cell carcinoma, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, papillary thyroid carcinoma, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pheochromocytoma, pituitary tumor, prostate cancer, posterior uveal melanoma, rare hematological disorders, metastatic renal cancer, rhabdoid tumor, rhabdomyosarcoma, sarcoma, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, synovial sarcoma, testicular cancer, thymic cancer, thymoma, thyroid metastasis, uterine cancer, or any combination thereof.
97. The method of claim 95, wherein the cancer comprises cervical cancer, lung cancer, liver cancer, ovarian cancer, skin cancer including melanoma and squamous cell carcinoma, colon cancer, bladder cancer, breast cancer, kidney cancer, esophageal cancer, stomach cancer, pancreatic cancer, head cancer, and neck cancer.
98. The antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, the immunoconjugate according to claim 47, or the pharmaceutical composition according to claim 73 for use as a medicament.
99. The antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, the immunoconjugate according to claim 47, or the pharmaceutical composition according to claim 73, for use as a medicament for the treatment of cancer, sepsis or septic shock, or chronic infection.
100. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, the immunoconjugate according to claim 47, or the pharmaceutical composition according to claim 73 for the manufacture of a medicament.
101. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the bispecific molecule according to claim 46, the immunoconjugate according to claim 47, or the pharmaceutical composition according to claim 73 for the manufacture of a medicament for treating cancer, sepsis or septic shock, or chronic infection.
102. A method of producing the antibody or antigen-binding fragment thereof according to any one of claims 1-38, the canine antibody according to any one of claims 39-41, or the scFv according to any one of claims 42-45, the method comprising culturing the host cell according to any one of claims 68-72.
103. The method of claim 102, further comprising incubating the host cell of any one of claims 68-72 in a cell culture medium under conditions sufficient to allow expression and secretion of the antibody or antigen-binding fragment thereof of any one of claims 1-38, the canine antibody of any one of claims 39-41, or the scFv of any one of claims 42-45.
Citation Information
Patent Citations
Salmonella promoter for heterologous gene expression
US20040131637A1
Novel nucleic acids and polypeptides
US20050196754A1
Chemical linkers and conjugates thereof
US20060024317A1
Target specific cross-linked heteroantibodies
US4676980A
Chemical vapor deposition wafer boat
US4694778A
Cited By
Monoclonal antibody targeting dog PD-1 protein
CN121824759A
